{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Jcvillasboas.jpg|frameless|upright=0.3|center]]
|<big>[[User:Jcvillasboas|J.C. Villasboas Bisneto, MD]]<br>Rochester, MN</big>
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Hodgkin_lymphoma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==ASBMT==
*'''2015:''' Perales et al. [https://www.bbmt.org/article/S1083-8791(15)00152-4/fulltext Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation]
==[http://www.esmo.org/ ESMO]==
*'''2018:''' Eichenauer et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Hodgkin-Lymphoma Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2014:''' Eichenauer et al. [https://annonc.oxfordjournals.org/content/25/suppl_3/iii70.full.pdf+html Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/25185243 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf NCCN Guidelines - Hodgkin Lymphoma]

=Untreated, early-stage favorable (ESF)=
''Note: the definition of early stage favorable varies across organizations, e.g., EORTC, GHSG, NCIC, and NCCN; see original definitions used in the trials for details.''

==ABVD {{#subobject:3065be|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Example orders===
*[[Example orders for ABVD in Hodgkin lymphoma]]
===Variant #1, 2 cycles {{#subobject:c39ab4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/23/3495.long Engert et al. 2007 (GHSG HD7)]
| style="background-color:#1a9851" |Phase III (E)
|No chemotherapy
| style="background-color:#1a9850" |Superior FFTF
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
| style="background-color:#1a9851" |Phase III (E)
|ABVD x 4
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="3" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
| rowspan="3" style="background-color:#1a9851" |Phase III (C)
|1. ABV
| style="background-color:#1a9850" |Superior FFTF
|-
|2. AV
| style="background-color:#1a9850" |Superior FFTF
|-
|3. [[#AVD|AVD]]
| style="background-color:#d9ef8b" |Might have superior FFTF
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*GHSG HD7: [[#Radiation_therapy_2|EFRT]]
*GHSG HD10: [[#Radiation_therapy_2|IFRT x 20 Gy]] versus [[#Radiation_therapy_2|IFRT x 30 Gy]]
*GHSG HD13: [[#Radiation_therapy_2|IFRT x 30 Gy]]

===Variant #2, 2 cycles with response adaptation {{#subobject:74ee38|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10 F)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128083/ Straus et al. 2018 (CALGB 50604)]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*EORTC/LYSA/FIL H10 F, negative interim PET-CT (1 or 2 points on the 5-point [[#Deauville_criteria_.282009.29|Deauville scale]]): 2 more cycles of ABVD ('''4 cycles total''') versus 1 more cycle of ABVD, then [[#Radiation_therapy_2|INRT]]
*EORTC/LYSA/FIL H10 F, positive interim PET-CT: [[#eBEACOPP_3|eBEACOPP]], then [[#Radiation_therapy_3|INRT]]
*CALGB 50604, negative interim PET-CT (1 to 3 points on the 5-point [[#Deauville_criteria_.282009.29|Deauville scale]]): 2 more cycles of ABVD ('''4 cycles total''')
*CALGB 50604, positive interim PET-CT: [[#eBEACOPP_3|eBEACOPP]] x 2, then [[#Radiation_therapy_3|IFRT]] x 30.6 Gy

===Variant #3, 3 cycles with response adaptation {{#subobject:0a2352|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 Radford et al. 2015 (UK NCRI RAPID)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*Negative interim PET-CT (1 or 2 points on the 5-point [[#Deauville_criteria_.282009.29|Deauville scale]]): [[#Radiation_therapy_2|IFRT]] versus [[#Observation|no further treatment]]
*Positive interim PET-CT: A [[#ABVD_4|fourth cycle of ABVD]], then [[#Radiation_therapy_3|IFRT]]

===Variant #4, 4 cycles {{#subobject:62aba8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.09.085 Meyer et al. 2005 (NCIC CTG/ECOG HD.6)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Radiation_therapy|STNI]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
| style="background-color:#1a9851" |Phase III (C)
|ABVD x 2
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: efficacy for NCIC CTG/ECOG HD.6 is based on the 2011 update.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*'''Bonadonna et al. 2004:''' [[#Radiation_therapy_2|IFRT]] versus [[#Radiation_therapy_2|STNI]]
*'''GHSG HD10:''' [[#Radiation_therapy_2|IFRT x 20 Gy]] versus [[#Radiation_therapy_2|IFRT x 30 Gy]]

===References===
# Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41. [http://jco.ascopubs.org/content/22/14/2835.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15199092 PubMed]
# '''NCIC CTG/ECOG HD.6:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18. [http://ascopubs.org/doi/10.1200/JCO.2005.09.085 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15837968 PubMed]
## '''Update:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408. Epub 2011 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111961 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932020/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149921 PubMed]
# '''GHSG HD7:''' Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502. [http://jco.ascopubs.org/content/25/23/3495.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17606976 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
# '''GHSG HD10:''' Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20818855 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.4181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23509310 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''EORTC/LYSA/FIL H10:''' Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
## '''Update:''' André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14. [http://ascopubs.org/doi/full/10.1200/JCO.2016.68.6394 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28291393 PubMed]
# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
# '''Retrospective:''' Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179-84. Epub 2015 Apr 19. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13419/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891777 PubMed]
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
# '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]
# '''CALGB 50604:''' Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018 Sep 6;132(10):1013-1021. Epub 2018 Jul 26. [http://www.bloodjournal.org/content/132/10/1013.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128083/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30049811 PubMed]

==AVD {{#subobject:7e0834|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Regimen {{#subobject:635312|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. ABV
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#ABVD|ABVD]]
| style="background-color:#fee08b" |Might have inferior FFTF
|-
|3. AV
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT x 30 Gy]]

===References===
# Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]

==MOPP-ABV {{#subobject:09f0a5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MOPP-ABV: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
===Regimen {{#subobject:0e0363|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]], 3 to 4 weeks later

===References===
# '''EORTC-GELA H8-F:''' Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]

==Radiation therapy {{#subobject:6298df|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 35 Gy of subtotal nodal irradiation (STNI) {{#subobject:b368c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.09.085 Meyer et al. 2005 (NCIC CTG/ECOG HD.6)]
| style="background-color:#1a9851" |Phase III (C)
|[[#ABVD|ABVD]]
| style="background-color:#fc8d59" |Seems to have inferior OS (*)
|-
|}
''Note: efficacy for NCIC CTG/ECOG HD.6 is based on the 2011 update.''
====Radiotherapy====
*[[External beam radiotherapy|STNI]] 35 Gy in 20 fractions

'''One course'''
===Variant #2, 36 Gy of STNI + 4 Gy boost {{#subobject:904206|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
| style="background-color:#1a9851" |Phase III (C)
|[[#MOPP-ABV|MOPP-ABV]], then [[#Radiation_therapy_2|IFRT]]
| style="background-color:#d73027" |Inferior OS
|-
|}
====Radiotherapy====
*[[External beam radiotherapy|STNI]] 36 Gy in 18 fractions, with 4 Gy boost to involved fields

'''One course'''
===Variant #3, 40 to 44 Gy of subtotal lymphoid irradiation (STLI) {{#subobject:a248c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.12.1822 Horning et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|IFRT, then VBM
| style="background-color:#fc8d59" |Seems to have inferior FFP
|-
|}
====Radiotherapy====
*[[External beam radiotherapy|STLI]] 40 to 44 Gy

'''One course'''
===References===
# Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol. 1988 Dec;6(12):1822-31. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.12.1822 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2462025 PubMed]
# Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JH, Le Fur R et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993 Nov;11(11):2258-72. [http://jco.ascopubs.org/content/11/11/2258.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7693881 PubMed]
# '''NCIC CTG/ECOG HD.6:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18. [http://ascopubs.org/doi/10.1200/JCO.2005.09.085 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15837968 PubMed]
## '''Update:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408. Epub 2011 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111961 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932020/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149921 PubMed]
# '''EORTC-GELA H8-F:''' Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]

==Stanford V {{#subobject:d5ed05|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d0048d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603439/ Advani et al. 2013 (G4)]
| style="background-color:#91cf61" |Non-randomized
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per week on weeks 1, 3, 5, 7
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per week on weeks 1, 3, 5, 7
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per week on weeks 1 & 5
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV twice per week (presumably on subsequent days) on weeks 3 & 7
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per week on weeks 2, 4, 6, 8
*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once per week on weeks 2, 4, 6, 8
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO every other day for 6 weeks, then tapered by 10 mg per day over the next 2 weeks

'''8-week course'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]], 1 to 3 weeks later

===References===
# Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013 Apr;24(4):1044-8. Epub 2012 Nov 7. '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603439/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23136225 PubMed]

==VAMP {{#subobject:4d666a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VAMP: '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethrotrexate,  '''<u>P</u>'''rednisone
===Regimen {{#subobject:6f694d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ Metzger et al. 2012 (HOD99)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''To be completed?''
====Chemotherapy====
*[[Vinblastine (Velban)]]
*[[Doxorubicin (Adriamycin)]]
*[[Methotrexate (MTX)]]
*[[Prednisone (Sterapred)]]

'''4 cycles'''
====Subsequent treatment====
*Early responders: [[#Observation|Observation]] versus [[#Radiation_therapy_2|RT]]
===References===
# '''HOD99:''' Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. [https://jamanetwork.com/journals/jama/fullarticle/1199151 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22735430 PubMed]

=Untreated, early-stage unfavorable (ESU)=
''Note: the definition of early stage unfavorable varies across organizations, e.g., EORTC, GHSG, NCIC, and NCCN; see original definitions used in the trials for details.''

==ABVD {{#subobject:0e1f18|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine

===Example orders===
*[[Example orders for ABVD in Hodgkin lymphoma]]

===Variant #1, 2 cycles {{#subobject:865dd5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.09.085 Meyer et al. 2005 (NCIC CTG/ECOG HD.6)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NCIC_CTG.2FECOG_HD.6|See link]]
|[[Complex_multipart_regimens#NCIC_CTG.2FECOG_HD.6|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*GHSG HD14: [[#eBEACOPP|Escalated BEACOPP]] x 2
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''

====Subsequent treatment====
*NCIC CTG/ECOG HD.6: [[#Radiation_therapy_2|STNI]]
*GHSG HD14: [[#Radiation_therapy_2|IFRT]] x 30 Gy

===Variant #2, 2 cycles with response adaptation {{#subobject:bcda9c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10 U)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''

====Subsequent treatment====
*Negative interim PET-CT (1 or 2 points on the 5-point Deauville scale): 4 more cycles of ABVD versus 2 more cycles of ABVD, then [[#Radiation_therapy_2|INRT]]
*Positive interim PET-CT: [[#eBEACOPP_3|eBEACOPP]], then [[#Radiation_therapy_3|INRT]]

===Variant #3, 4 cycles {{#subobject:c4907d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.09.085 Meyer et al. 2005 (NCIC CTG/ECOG HD.6)]
| style="background-color:#1a9851" |Phase III (E)
|ABVD x 2, then [[#Radiation_therapy_2|STNI]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|-
|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|-
|}
''Note: efficacy for NCIC CTG/ECOG HD.6 is based on the 2011 update.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*GHSG HD11: [[#Radiation_therapy_2|IFRT]] x 20 Gy versus [[#Radiation_therapy_2|IFRT]] x 30 Gy
*GHSG HD14: [[#Radiation_therapy_2|IFRT]] x 30 Gy

===Variant #4, 6 to 8 cycles {{#subobject:44b42c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/11/11/2258.long Carde et al. 1993 (EORTC H6U)]
| style="background-color:#1a9851" |Phase III (E)
|MOPP
| style="background-color:#1a9850" |Superior FFP
|-
|[http://www.bloodjournal.org/content/104/12/3483.long Straus et al. 2004]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ Gordon et al. 2012 (ECOG E2496)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Stanford_V_2|Stanford V]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: EORTC H6U included radiation delivered between cycles 3 & 4. Straus et al. 2004 enrolled patients with stages I, II, and IIIA nonbulky disease and did not distinguish between favorable or unfavorable subtypes. ECOG E2496 gives a range of cycles.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 6 to 8 cycles'''
====Subsequent treatment====
*EORTC H6U & ECOG E2496: [[#Radiation_therapy_2|IFRT]] x 36 Gy
*Straus et al. 2004: [[#Radiation_therapy_2|EFRT]] x 36 Gy versus [[#Observation|no further treatment]]

===References===
# '''EORTC H6U:''' Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JH, Le Fur R, Somers R, Kluin-Nelemans HC, Busson A, Breed WP, Bron D, Holdrinet A, Rutten EH, Michiels JJ, Regnier R, Debusscher L, Musella R, Fargeot P, Thyss A, Cattan A, Rigal-Huguet F, Roth S, Caillou B, Dupouy N, Henry-Amar M. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993 Nov;11(11):2258-72. [http://jco.ascopubs.org/content/11/11/2258.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7693881 PubMed]
# Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9. Epub 2004 Aug 17. [http://www.bloodjournal.org/content/104/12/3483.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15315964 PubMed]
# '''NCIC CTG/ECOG HD.6:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18. [http://ascopubs.org/doi/10.1200/JCO.2005.09.085 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15837968 PubMed]
## '''Update:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408. Epub 2011 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111961 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932020/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149921 PubMed]
# '''GHSG HD11:''' Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.4181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23509310 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
# '''GHSG HD14:''' von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
# '''ECOG E2496:''' Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
## '''Subgroup analysis:''' Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''EORTC/LYSA/FIL H10:''' Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
## '''Update:''' André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14. [http://ascopubs.org/doi/full/10.1200/JCO.2016.68.6394 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28291393 PubMed]
# '''Retrospective:''' Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179-84. Epub 2015 Apr 19. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13419/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891777 PubMed]

==A+AVD {{#subobject:d609fa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
A+AVD: '''<u>A</u>'''dcetris (Brentuximab vedotin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
<br>BV + AVD: '''<u>B</u>'''rentuximab '''<u>V</u>'''edotin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Regimen {{#subobject:dce193|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025897/ Kumar et al. 2016]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once per day on days 1 & 15
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients with a negative repeat PET-CT: [[#Radiation_therapy_2|ISRT]]

===References===
# Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. Epub 2016 Jul 25. [http://www.bloodjournal.org/content/128/11/1458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025897/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27458003 PubMed]

==BEACOPP {{#subobject:053c14|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>BEACOPP<sub>baseline</sub>
===Regimen {{#subobject:9b724c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]] x 20 Gy versus [[#Radiation_therapy_2|IFRT]] x 30 Gy

===References===
# '''GHSG HD11:''' Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27)99-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]

==eBEACOPP {{#subobject:e0cab9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
eBEACOPP: '''<u>e</u>'''scalated '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Regimen {{#subobject:7d82bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

====Supportive medications====
*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 8, continues until ANC greater than 1000/uL for 3 consecutive days

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#ABVD_2|ABVD]] x 2, then [[#Radiation_therapy_2|IFRT]] x 30 Gy

===References===
<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
# '''GHSG HD14:''' von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]

==EBVP {{#subobject:075ef7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EBVP: '''<u>E</u>'''pirubicin, '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>P</u>'''rednisone
===Regimen {{#subobject:3b78aa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.redjournal.org/article/S0360-3016(17)33984-6/fulltext Thomas et al. 2017 (EORTC-GELA H9-F)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or IM once on day 1
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]] x 20 Gy versus [[#Radiation_therapy_2|IFRT]] x 36 Gy versus [[#Observation|no further treatment]]
===References===
# '''EORTC-GELA H9-F:''' Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. Epub 2017 Oct 27. [https://www.redjournal.org/article/S0360-3016(17)33984-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29229324 PubMed]

==MOPP-ABV {{#subobject:2a2ed7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MOPP-ABV: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
===Variant #1, 4 cycles {{#subobject:ac2cb7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]] versus [[#Radiation_therapy_2|STNI]], in 3 to 4 weeks

===Variant #2, 6 cycles {{#subobject:f688a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.2746 Noordijk et al. 2006 (EORTC H7-U)]
| style="background-color:#1a9851" |Phase III (C)
|EBVD
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]], in 3 to 4 weeks

===References===
# '''EORTC H7-U:''' Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006 Jul 1;24(19):3128-35. Epub 2006 Jun 5. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.2746 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16754934 PubMed]
# '''EORTC-GELA H8-U:''' Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]

==RABVD {{#subobject:57ac1e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RABVD: '''<u>R</u>'''ituximab, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Regimen {{#subobject:dd6eed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359734/ Kasamon et al. 2012]
| style="background-color:#ffffbe" |Phase II, <20 pts in subgroup
|-
|}
''Patients were NOT required to have CD20+ disease.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Pre-phase: 375 mg/m<sup>2</sup> IV once one week prior to cycle 1 of ABVD
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Cycles 2, 4, 6: 375 mg;m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 6 to 8 cycles'''

===References===
# Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. Epub 2012 Feb 16. [http://bloodjournal.hematologylibrary.org/content/119/18/4129.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359734/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22343727 PubMed]

==Stanford V {{#subobject:50d745|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e33d2b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ Gordon et al. 2012 (ECOG E2496)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_2|ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''In the Advani et al. 2015 subgroup analysis, the Stanford V regimen is described as "once per week for 12 weeks." However, the regimen has previously been described as being 4-week cycles for 3 cycles (same duration, but schedule is different). Until this discrepancy is resolved, we replicate the 4-week cycle version here:''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 15 & 16 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 22 
*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once per day on days 8 & 22
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO every other day (with taper)

'''28-day cycle for 3 cycles'''

====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]] x 36 Gy

===References===
# '''ECOG E2496:''' Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
## '''Subgroup analysis:''' Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]

=Untreated, advanced stage=
''Note: the definition of advanced stage varies across organizations, e.g., EORTC, GHSG, NCIC, and NCCN; see original definitions used in the trials for details.''

==ABVD {{#subobject:8b9772|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine

===Example orders===
*[[Example orders for ABVD in Hodgkin lymphoma]]

===Variant #1, 2 cycles with response adaptation {{#subobject:a8fbc8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/34/12/1376.full Zinzani et al. 2016 (HD0801)]
| style="background-color:#91cf61" |Non-randomized
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/ Press et al. 2016 (SWOG S0816)]
| style="background-color:#91cf61" |Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ Johnson et al. 2016 (RATHL)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 Gallamini et al. 2018 (GITIL/FIL HD 0607)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*HD0801, negative PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]]: 4 more cycles of ABVD (6 total)
*HD0801, positive PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]]: [[#IGEV|IGEV]] salvage
*SWOG S0816 & GITIL/FIL HD 0607, negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3): 4 more cycles of ABVD (6 total)
*SWOG S0186, positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5): [[#eBEACOPP_3|Escalated BEACOPP]] salvage
*RATHL, negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3): 4 more cycles of ABVD (6 total) versus [[#AVD|AVD]] x 4
*RATHL, positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5): [[#eBEACOPP_3|Escalated BEACOPP]] or [[#BEACOPP-14_2|BEACOPP-14]] salvage, specified in advance
*GITIL/FIL HD 0607, positive PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (4 or 5): [[#eBEACOPP_3|eBEACOPP]] versus R-BEACOPP

===Variant #2, 6 cycles {{#subobject:2544df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.907 Gobbi et al. 2005 (GITIL HD9601)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. MOPPEBVCAD
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Modified Stanford V
| style="background-color:#1a9850" |Superior FFS
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0910 Federico et al. 2009 (GITIL/FIL HD2000)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. [[#eBEACOPP_2|eBEACOPP]] x 4, then [[#BEACOPP_2|BEACOPP]] x 2
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|2. CEC
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/34/12/1376.full Zinzani et al. 2016 (HD0801)]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/ Press et al. 2016 (SWOG S0816)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ Johnson et al. 2016 (RATHL)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1708984 Connors et al. 2017 (ECHELON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#A+AVD_2|A+AVD]]
| style="background-color:#fc8d59" |Seems to have inferior modified PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 Gallamini et al. 2018 (GITIL/FIL HD 0607)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: Zinzani et al. 2016 does not describe the details of radiotherapy. Note that ECHELON-1 specifies "up to" 6 cycles of therapy, but does not explain circumstance in which fewer than 6 would be given. Efficacy for GITIL/FIL HD2000 is based on the 2015 update.''
====Preceding treatment====
*HD0801: ABVD x 2, with negative PET-CT by [[#Juweid.27s_criteria_.282007.29|Juweid's criteria]]
*SWOG S0186, RATHL, GITIL/FIL HD 0607: ABVD x 2, with negative PET-CT by [[#Deauville_criteria_.282010.29|Deauville score]] (1 to 3)
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 6 cycles (see note)'''
====Subsequent treatment====
*Gobbi et al. 2005: conditioned [[#Radiation_therapy_2|Radiotherapy]]
*HD0801, with initial bulky disease: [[#Observation|Observation]] versus [[#Radiation_therapy_2|Radiotherapy]]

===Variant #3, 8 cycles (ABVD<sub>8</sub>) {{#subobject:e8872e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197507%2936%3A1%3C252%3A%3AAID-CNCR2820360128%3E3.0.CO%3B2-7 Bonadonna et al. 1975]
| style="background-color:#1a9851" |Phase III (E)
|[[#MOPP|MOPP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/5/1/27.long Santoro et al. 1987]
| style="background-color:#1a9851" |Phase III (E)
|[[#MOPP|MOPP]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
| rowspan="2" |[https://www.nejm.org/doi/10.1056/NEJM199211193272102 Canellos et al. 1992 (CALGB 8251)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#MOPP|MOPP]]
| style="background-color:#91cf60" |Seems to have superior EFS (*)
|-
|2. [[Hodgkin_lymphoma_-_historical#MOPP.2FABVD|MOPP/ABVD]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.086 Duggan et al. 2003 (CALGB-8952)]
| style="background-color:#1a9851" |Phase III (C)
|[[#MOPP-ABV_3|MOPP-ABV]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.2151 Johnson et al. 2005 (UKLG LY09)]
|style="background-color:#1a9851" |Phase III (C)
|1. ChlVPP/EVA<br> 2. [[Hodgkin_lymphoma_-_historical#ChlVPP.2FPABIOE|ChlVPP/PABlOE]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/27/32/5390.long Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Stanford_V_2|Stanford V]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011 (GSM-HD)]
| style="background-color:#1a9851" |Phase III (C)
|[[#eBEACOPP_2|Escalated BEACOPP]], then [[#BEACOPP_2|BEACOPP]]
| style="background-color:#fc8d59" |Seems to have inferior FFFP
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ Gordon et al. 2013 (ECOG E2496)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Stanford_V_2|Stanford V]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
| style="background-color:#1a9851" |Phase III (C)
|[[#eBEACOPP_2|Escalated BEACOPP]], then [[#BEACOPP_2|BEACOPP]]
| style="background-color:#fee08b" |Might have inferior EFS
|-
|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
| style="background-color:#1a9851" |Phase III (C)
|[[#eBEACOPP_2|Escalated BEACOPP]], then [[#BEACOPP_2|BEACOPP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Duggan et al. 2003 specified that chemotherapy was given until CR plus an additional two cycles, for a minimum of eight cycles and a maximum of 10 cycles. Reported efficacy for CALGB 8251 is based on the 2009 update.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 8 cycles'''

===References===
# Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197507%2936%3A1%3C252%3A%3AAID-CNCR2820360128%3E3.0.CO%3B2-7 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/54209 PubMed]
# Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, Tesoro-Tess JD, Banfi A. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. [http://jco.ascopubs.org/content/5/1/27.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2433409 PubMed]
# '''CALGB 8251:''' Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. [https://www.nejm.org/doi/10.1056/NEJM199211193272102 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1383821 PubMed]
## '''Update:''' Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 2;346(18):1417-8. [https://www.nejm.org/doi/10.1056/NEJM200205023461821 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11986425 PubMed]
## '''Update:''' Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10;361(24):2390-1. [https://www.nejm.org/doi/10.1056/NEJMc0906731 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20007568 PubMed]
# '''CALGB-8952:''' Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.086 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12586796 PubMed]
# '''GITIL HD9601:''' Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.907 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16172458 PubMed]
## '''Update:''' Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol. 2011 Nov 10;29(32):4227-33. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.9799 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990405 PubMed]
# '''UKLG LY09:''' Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.2151 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16314615 PubMed]
## '''Subgroup analysis:''' Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. Epub 2010 May 24. [http://ascopubs.org/doi/full/10.1200/JCO.2009.26.0323 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20498402 PubMed]
# '''GITIL/FIL HD2000:''' Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10;27(5):805-11. Epub 2009 Jan 5. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0910 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19124807 PubMed]
## '''Update:''' Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175-81. Epub 2015 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.4817 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26712220 PubMed]
<!-- Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December, 6-9, 2008; and in part at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June, 7-11, 2005. -->
# '''UK NCRI ISRCTN 64141244:''' Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/32/5390.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19738111 PubMed]
<!-- Presented in part at the 44th annual meeting of the American Society of Clinical Oncology, Chicago, May 30–June 3, 2008. -->
# '''GSM-HD:''' Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
# '''ECOG E2496:''' Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
## '''Subgroup analysis:''' Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
# '''LYSA H34:''' Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
# '''Retrospective:''' Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179-84. Epub 2015 Apr 19. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13419/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891777 PubMed]
# '''HD0801:''' Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/12/1376.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26884559 PubMed]
# '''SWOG S0816:''' Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. [http://jco.ascopubs.org/content/34/17/2020.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27069074 PubMed]
# '''EORTC 20012:''' Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight cycles of ABVD versus four cycles of BEACOPP<sub>escalated</sub> plus four cycles of BEACOPP<sub>baseline</sub> in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
# '''RATHL:''' Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [https://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
# '''ECHELON-1:''' Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018 Jan 25;378(4):331-344. Epub 2017 Dec 10. [https://www.nejm.org/doi/full/10.1056/NEJMoa1708984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29224502 PubMed]
# '''GITIL/FIL HD 0607:''' Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018 Feb 10;36(5):454-462. Epub 2018 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29360414 PubMed]

==ABVD, DD-DI {{#subobject:fb0584|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVD, DD-DI: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>D</u>'''ose-'''<u>D</u>'''ense and '''<u>D</u>'''ose-'''<u>I</u>'''ntense

===Regimen {{#subobject:bfb2a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full Russo et al. 2014]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] as follows:
**Cycles 1 to 4: 35 mg/m<sup>2</sup> IV once per day on days 1 & 11
**Cycles 5 & 6: 25 mg/m<sup>2</sup> IV once per day on days 1 & 11
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 11
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 11
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once on days 1 & 11

====Supportive medications====
*[[Lenograstim (Granocyte)]] 263 mcg SC once per day on days 6 to 8 and days 17 to 19 (6 doses per cycle)

'''21-day cycle for 6 cycles'''

===References===
# Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. A phase II study of dose-dense and dose-intense ABVD (ABVD(DD-DI) ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):118-29. Epub 2014 Mar 27. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12862/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24673727 PubMed]

==AVD {{#subobject:98fbb5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine

===Regimen {{#subobject:75ea56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ Johnson et al. 2016 (RATHL)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_3|ABVD]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Preceding treatment====
*[[#ABVD_3|ABVD]] x 2
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 4 cycles'''

===References===
# '''RATHL:''' Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [https://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]

==A+AVD {{#subobject:b608e8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
A+AVD: '''<u>A</u>'''dcetris (Brentuximab vedotin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
<br>B-AVD: '''<u>B</u>'''rentuximab vedotin, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
<br>AVD-A: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>A</u>'''dcetris (Brentuximab vedotin)
===Regimen {{#subobject:26c282|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70501-1/fulltext Younes et al. 2013]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1708984 Connors et al. 2017 (ECHELON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_3|ABVD]]
| style="background-color:#91cf60" |Seems to have superior modified PFS
|-
|}
''Younes et al. 2013 was a phase I trial but had greater than 20 patients in the MTD expansion cohort.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once per day on days 1 & 15, '''given fourth, within about 1 hour of AVD infusion completion'''
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for up to 6 cycles'''

====Subsequent treatment====
*Younes et al. 2013: Consolidative radiotherapy was permitted at the investigator's discretion

===References===
# Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348-56. Epub 2013 Nov 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70501-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24239220 PubMed]
<!-- ## '''Update: Abstract:''' Joseph M Connors, MD, Stephen Ansell, Steven I. Park, MD, Michelle A. Fanale, M.D. and Anas Younes. Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. ASH Annual Meeting 2014, Abstract 292 [https://ash.confex.com/ash/2014/webprogram/Paper69855.html link to abstract] -->
## '''Update:''' Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017 Sep 14;130(11):1375-1377. Epub 2017 Jul 21. [http://www.bloodjournal.org/content/130/11/1375.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28733323 PubMed]
# '''ECHELON-1:''' Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018 Jan 25;378(4):331-344. Epub 2017 Dec 10. [https://www.nejm.org/doi/full/10.1056/NEJMoa1708984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29224502 PubMed]

==BEACOPP {{#subobject:2720ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>bBEACOPP: '''<u>b</u>'''aseline '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Variant #1, 4 cycles {{#subobject:4b5469|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011 (GSM-HD)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Viviani_et_al._2011_.28IIL.29|See link]]
|[[Complex_multipart_regimens#Viviani_et_al._2011_.28IIL.29|See link]]
|-
|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|-
|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#LYSA_H34|See link]]
|[[Complex_multipart_regimens#LYSA_H34|See link]]
|-
|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC_20012|See link]]
|[[Complex_multipart_regimens#EORTC_20012|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#eBEACOPP_2|Escalated BEACOPP]] x 4
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 mcg SC once per day, starting day 8, continues until ANC greater than 1000/uL for 3 consecutive days (GSM-HD) or until day 14 (LYSA H34)

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*GHSG HD12 patients with initial bulky or residual disease: [[#Radiation_therapy_2|ISRT]] x 30 Gy versus [[#Observation|no further treatment]]

===Variant #2, 8 cycles {{#subobject:4e6661|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/8/2/143.long Diehl et al. 1997]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#f7fcfd" |ORR: 93%
|-
| rowspan="2" |[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#eBEACOPP_2|Escalated dose BEACOPP]]
| style="background-color:#d73027" |Inferior FFTF
|-
|2. [[Hodgkin_lymphoma_-_historical#COPP.2FABVD|COPP/ABVD]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Note that this is technically "BEACOPP II." The original "BEACOPP I" is detailed in Diehl et al. 1997 but is of historical interest, only.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 8 cycles'''

===References===
# Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H; The German Hodgkin's Lymphoma Study Group. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol. 1997 Feb;8(2):143-8. [http://annonc.oxfordjournals.org/content/8/2/143.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9093722 PubMed]
# '''GHSG HD9:''' Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. [http://jco.ascopubs.org/content/16/12/3810.long link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9850026 PubMed]
## '''Update:''' Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. Erratum in: N Engl J Med. 2005 Aug 18;353(7):744. [https://www.nejm.org/doi/full/10.1056/NEJMoa022473 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802024 PubMed]
## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [http://jco.ascopubs.org/content/27/27/4548.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19704068 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
# '''GITIL/FIL HD2000:''' Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10;27(5):805-11. Epub 2009 Jan 5. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0910 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19124807 PubMed]
## '''Update:''' Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175-81. Epub 2015 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.4817 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26712220 PubMed]
<!-- Presented in part at the 44th annual meeting of the American Society of Clinical Oncology, Chicago, May 30–June 3, 2008. -->
# '''GSM-HD:''' Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
# '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
# '''LYSA H34:''' Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
# '''EORTC 20012:''' Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight cycles of ABVD versus four cycles of BEACOPP<sub>escalated</sub> plus four cycles of BEACOPP<sub>baseline</sub> in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]

==BEACOPP-14 {{#subobject:5086b5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP-14: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>14</u>'''-day course
===Regimen {{#subobject:5e1855|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/9/1734.full Sieber et al. 2003]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#eBEACOPP_2|Escalated BEACOPP]] x 8
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#eBEACOPP_2|Escalated BEACOPP]] x 6
| style="background-color:#eeee01" |Non-inferior FFTF
|-
|}
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 7

====Supportive medications====
*[[Filgrastim (Neupogen)]] as follows:
**<75 kg body weight: 300 mcg SC once per day on days 8 to 13
**greater than or equal to 75 kg body weight: 480 mcg SC once per day on days 8 to 13

'''14-day cycle for 8 cycles'''

===References===
# Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 May 1;21(9):1734-9. [http://jco.ascopubs.org/content/21/9/1734.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12721249 PubMed]
# '''GHSG HD15:''' Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22480758 PubMed]

==eBEACOPP {{#subobject:d6794|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
eBEACOPP: '''<u>e</u>'''scalated '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>escBEACOPP: '''<u>esc</u>'''alated '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>BEACOPP(escalated): '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, escalated dose
===Example orders===
*[[Example orders for escalated dose BEACOPP in Hodgkin lymphoma]]
===Variant #1, 2 cycles with response adaptation {{#subobject:ff4031|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*PET-negative, prior to June 2011: eBEACOPP x 6 (total) versus eBEACOPP x 8 (total)
*PET-negative, after June 2011: eBEACOPP x 4 (total) versus eBEACOPP x 6 (total)
*PET-positive, prior to June 2011: [[#eBEACOPP_3|eBEACOPP]] x 8 (total) versus R-eBEACOPP x 8 (total)
*PET-positive, after June 2011: [[#eBEACOPP_3|eBEACOPP]] x 6 (total)

===Variant #2, 4 cycles {{#subobject:17f536|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 Viviani et al. 2011 (GSM-HD)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Viviani_et_al._2011_.28IIL.29|See link]]
|[[Complex_multipart_regimens#Viviani_et_al._2011_.28IIL.29|See link]]
|-
|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|-
|[http://annonc.oxfordjournals.org/content/25/8/1622.full.html Mounier et al. 2014 (LYSA H34)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#LYSA_H34|See link]]
|[[Complex_multipart_regimens#LYSA_H34|See link]]
|-
|[http://jco.ascopubs.org/content/34/17/2028.full Carde et al. 2016 (EORTC 20012)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC_20012|See link]]
|[[Complex_multipart_regimens#EORTC_20012|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#1a9851" |Phase III (C)
|1. eBEACOPP x 6<br> 2. eBEACOPP x 8
| style="background-color:#eeee01" |Non-inferior PFS (*)
|-
|}
''Note: except for '''GHSG HD18''', this is a component of a sequential treatment protocol. Efficacy for '''GHSG HD18''' is based on the 2017 update.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 mcg SC once per day, starting day 8, continues until ANC greater than 1000/uL for 3 consecutive days (GSM-HD) or until day 14 (LYSA H34)

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*All '''except''' GHSG HD18: [[#BEACOPP_2|BEACOPP]] x 4

===Variant #3, 6 cycles {{#subobject:c1998e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#BEACOPP-14|BEACOPP-14]]
| style="background-color:#eeee01" |Non-inferior FFTF
|-
|2. Escalated BEACOPP x 8
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#1a9851" |Phase III (C)
|1. eBEACOPP x 4<br> 2. eBEACOPP x 8
| style="background-color:#eeee01" |Non-inferior PFS (*)
|-
|}
''Details are not available in the abstracts; it is assumed that the regimen is identical to escalated BEACOPP x 8, with 2 fewer cycles. Efficacy for '''GHSG HD18''' is based on the 2017 update.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 6 cycles'''

===Variant #4, 8 cycles {{#subobject:e16aa2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/16/12/3810.long Diehl et al. 1998 (GHSG HD9)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#BEACOPP_2|BEACOPP]]
| style="background-color:#1a9850" |Superior FFTF
|-
|2. [[Hodgkin_lymphoma_-_historical#COPP.2FABVD|COPP/ABVD]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|style="background-color:#eeee01"|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext Engert et al. 2012 (GHSG HD15)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#BEACOPP-14|BEACOPP-14]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. Escalated BEACOPP x 6
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#1a9851" |Phase III (C)
|1. eBEACOPP x 4<br> 2. eBEACOPP x 6
| style="background-color:#eeee01" |Non-inferior PFS (*)
|-
|}
''Efficacy for '''GHSG HD18''' is based on the 2017 update.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*GHSG HD12 patients with initial bulky or residual disease: [[#Radiation_therapy_2|ISRT]] x 30 Gy versus [[#Observation|no further treatment]]
===References===
# '''GHSG HD9:''' Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. [http://jco.ascopubs.org/content/16/12/3810.long link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9850026 PubMed]
## '''Update:''' Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. Erratum in: N Engl J Med. 2005 Aug 18;353(7):744. [https://www.nejm.org/doi/full/10.1056/NEJMoa022473 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802024 PubMed]
## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [http://jco.ascopubs.org/content/27/27/4548.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19704068 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
# '''GITIL/FIL HD2000:''' Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10;27(5):805-11. Epub 2009 Jan 5. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0910 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19124807 PubMed]
## '''Update:''' Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175-81. Epub 2015 Dec 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.4817 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26712220 PubMed]
<!-- Presented in part at the 44th annual meeting of the American Society of Clinical Oncology, Chicago, May 30–June 3, 2008. -->
# '''GSM-HD:''' Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12. [https://www.nejm.org/doi/full/10.1056/NEJMoa1100340 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21774708 PubMed]
# '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
# '''GHSG HD15:''' Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61940-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22480758 PubMed]
# '''LYSA H34:''' Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug;25(8):1622-8. Epub 2014 May 14. [http://annonc.oxfordjournals.org/content/25/8/1622.full.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827123 PubMed]
# '''EORTC 20012:''' Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight cycles of ABVD versus four cycles of BEACOPP<sub>escalated</sub> plus four cycles of BEACOPP<sub>baseline</sub> in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. Epub 2016 Apr 25. [http://jco.ascopubs.org/content/34/17/2028.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27114593 PubMed]
# '''GHSG HD18:''' Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017 Apr;18(4):454-463. Epub 2017 Feb 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28236583 PubMed]
## '''Update:''' Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017 Dec 23;390(10114):2790-2802. Epub 2017 Oct 20. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32134-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29061295 PubMed]

==C-MOPP/ABV {{#subobject:e8ed3b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
C-MOPP/ABV: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
===Regimen {{#subobject:31ba72|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000501)88:9%3C2142::AID-CNCR21%3E3.0.CO;2-M/full Montoto et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 3 mg) IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once on day 8
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 8 cycles'''

*'''25 to 40 Gy of radiation therapy''' given over extended fields (mantle or inverted "Y" type) to patients with bulky disease or ones with residual disease after completion of chemotherapy

===References===
# Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer. 2000 May 1;88(9):2142-8. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000501)88:9%3C2142::AID-CNCR21%3E3.0.CO;2-M/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10813727 PubMed]]

==MOPP {{#subobject:bcde0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MOPP: '''<u>M</u>'''echlorethamine, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone

===Variant #1, 8 cycles, prednisone 25 mg/m<sup>2</sup> {{#subobject:fe82c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/12/2/279.long Somers et al. 1994]
| style="background-color:#1a9851" |Phase III (C)
|[[Hodgkin_lymphoma_-_historical#MOPP.2FABVD|MOPP/ABVD]]
| style="background-color:#fc8d59" |Seems to have inferior FFS
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (dose is capped at 2 mg) IV once per day on days 1 & 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Prednisone (Sterapred)]] 25 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 8 cycles'''

===Variant #2, capped vincristine {{#subobject:7e60d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJM199211193272102 Canellos et al. 1992 (CALGB 8251)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#ABVD_3|ABVD]]
| style="background-color:#fc8d59" |Seems to have inferior EFS (*)
|-
|2. [[Hodgkin_lymphoma_-_historical#MOPP.2FABVD|MOPP/ABVD]]
| style="background-color:#fc8d59" |Seems to have inferior EFS (*)
|-
|}
''Note: Reported efficacy is based on the 2009 update.''
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (dose is capped at 2 mg) IV once per day on days 1 & 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 6 to 8 cycles'''

===Variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annals.org/aim/article-abstract/684972/combination-chemotherapy-treatment-advanced-hodgkin-s-disease Devita et al. 1970]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://jamanetwork.com/journals/jama/article-abstract/350326 Stutzman & Glidewell 1973]
| style="background-color:#1a9851" |Phase III (E)
|1. ALB<br> 2. SEQ
| style="background-color:#1a9850" |Superior ORR
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197507)36:1%3C252::AID-CNCR2820360128%3E3.0.CO;2-7/abstract Bonadonna et al. 1975]
| style="background-color:#1a9851" |Phase III (C)
|[[#ABVD_5|ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="3" |[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract Cooper et al. 1980]
| rowspan="3" style="background-color:#1a9851" |Phase III (C)
|1. [[Hodgkin_lymphoma_-_historical#COPP_.28CCNU.29|COPP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[Hodgkin_lymphoma_-_historical#CVPP|CVPP]]
| style="background-color:#fc8d59" |Seems to have inferior CR rate
|-
|3. [[Hodgkin_lymphoma_-_historical#MVPP|MVPP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198204013061303 Santoro et al. 1982]
| style="background-color:#1a9851" |Phase III (C)
|[[Hodgkin_lymphoma_-_historical#MOPP.2FABVD|MOPP/ABVD]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://jco.ascopubs.org/content/5/1/27.long Santoro et al. 1987]
| style="background-color:#1a9851" |Phase III (C)
|[[#ABVD_3|ABVD]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/9/8/1409.long Longo et al. 1991]
| style="background-color:#1a9851" |Phase III (C)
|MOPP/CABS
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 6 to 8 cycles'''

===Variant #4, BNLI variant {{#subobject:7e52d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/S0140673676908333 Jelliffe 1976]
| style="background-color:#1a9851" |Phase III (C)
|TNI
| style="background-color:#d73027" |Inferior DFS
|-
|[https://www.thegreenjournal.com/article/S0167-8140(86)80032-9/pdf Hancock 1986]
| style="background-color:#1a9851" |Phase III (C)
|[[Hodgkin_lymphoma_-_historical#LOPP|LOPP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> (maximum dose of 15 mg) IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> (maximum dose of 200 mg) PO once per day on days 1 to 10
*[[Prednisone (Sterapred)]] 25 mg/m<sup>2</sup> (maximum dose of 60 mg) PO once per day on days 1 to 14

'''28-day cycle for at least 6 cycles'''

===References===
# Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881-95. [http://annals.org/aim/article-abstract/684972/combination-chemotherapy-treatment-advanced-hodgkin-s-disease link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/5525541 PubMed] content property of [http://hemonc.org HemOnc.org]
# Stutzman L, Glidewell O. Multiple chemotherapeutic agents for Hodgkin disease: comparison of three routines: a cooperative study by acute leukemia group B. JAMA. 1973 Sep 3;225(10):1202-11. [https://jamanetwork.com/journals/jama/article-abstract/350326 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/4740983 PubMed]
# Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975 Jul;36(1):252-9. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197507)36:1%3C252::AID-CNCR2820360128%3E3.0.CO;2-7/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/54209 PubMed]
# Jelliffe AM; British National Lymphoma Investigation. Initial treatment of stage IIIA Hodgkin's disease: comparison of radiotherapy  with combined chemotherapy. Lancet. 1976 Nov 6;2(7993):991-5. [https://www.sciencedirect.com/science/article/pii/S0140673676908333 link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/62265 PubMed]
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7397630 PubMed]
# Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982 Apr 1;306(13):770-5. [https://www.nejm.org/doi/full/10.1056/NEJM198204013061303 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6174865 PubMed]
## '''Update:''' Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. [http://annals.org/article.aspx?articleid=700485 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2422994 PubMed]
# Hancock BW; British National Lymphoma Investigation. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Radiother Oncol. 1986 Nov;7(3):215-21. [https://www.thegreenjournal.com/article/S0167-8140(86)80032-9/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3544084 PubMed]
## '''Update:''' Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Br J Cancer. 1991 Apr;63(4):579-82. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/3544084 PubMed]
# Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, Tesoro-Tess JD, Banfi A. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37. [http://jco.ascopubs.org/content/5/1/27.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2433409 PubMed]
# Longo DL, Duffey PL, DeVita VT Jr, Wiernik PH, Hubbard SM, Phares JC, Bastian AW, Jaffe ES, Young RC. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol. 1991 Aug;9(8):1409-20. [http://jco.ascopubs.org/content/9/8/1409.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1712836 PubMed]
# '''CALGB 8251:''' Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. [https://www.nejm.org/doi/10.1056/NEJM199211193272102 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1383821 PubMed]
## '''Update:''' Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 2;346(18):1417-8. [https://www.nejm.org/doi/10.1056/NEJM200205023461821 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11986425 PubMed]
## '''Update:''' Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10;361(24):2390-1. [https://www.nejm.org/doi/10.1056/NEJMc0906731 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20007568 PubMed]
# Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, Burgers JMV, Eghbali H, Zittoun R. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994 Feb;12(2):279-87. [http://jco.ascopubs.org/content/12/2/279.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7509381 PubMed]

==MOPP-ABV {{#subobject:e2a0a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MOPP-ABV: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine
<br>MOPP-ABV hybrid
===Regimen {{#subobject:5336ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/3/9/1174.abstract Klimo et al. 1985]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/15/4/1638.long Connor et al. 1997 (NCIC CTG HD4)]
| style="background-color:#1a9851" |Phase III (E)
|[[Hodgkin_lymphoma_-_historical#MOPP.2FABVD|MOPP/ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/16/1/19.abstract Glick et al. 1998]
| style="background-color:#1a9851" |Phase III (E)
|MOPP, then ABVD
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.086 Duggan et al. 2003 (CALGB-8952)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_3|ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa022628 Aleman et al. 2003 (EORTC 20884)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Chemotherapy====
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 8
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 6 to 8 cycles'''

====Subsequent treatment====
*EORTC 20884, CR: [[#Radiation_therapy_2|IFRT]] x 24 Gy versus [[#Observation|no further treatment]]
*EORTC 20884, PR: [[#Radiation_therapy_2|IFRT]] x 30 Gy versus [[#Observation|no further treatment]]

===References===
# Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985 Sep;3(9):1174-82. [http://jco.ascopubs.org/content/3/9/1174.abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2411881 PubMed]
# '''NCIC CTG HD4:''' Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. [http://jco.ascopubs.org/content/15/4/1638.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9193364 PubMed]
# Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan;16(1):19-26. [http://jco.ascopubs.org/content/16/1/19.abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9440718 PubMed]
# '''CALGB-8952:''' Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.086 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12586796 PubMed]
# '''EORTC 20884:''' Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. [https://www.nejm.org/doi/10.1056/NEJMoa022628 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802025 PubMed]

==RABVD {{#subobject:235eb9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RABVD: '''<u>R</u>'''ituximab, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine

===Variant #1 {{#subobject:54b9f3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359733/ Younes et al. 2012]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week x 6 weeks
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 6 cycles (except rituximab, which is given for a total of 6 doses)'''

===Variant #2 {{#subobject:314369|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359734/ Kasamon et al. 2012]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Pre-phase: 375 mg/m<sup>2</sup> IV once one week prior to cycle 1 of ABVD
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Cycles 2, 4, 6: 375 mg;m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 6 to 8 cycles'''

===References===
# Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4123-8. Epub 2012 Feb 27. [http://bloodjournal.hematologylibrary.org/content/119/18/4123.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359733/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22371887 PubMed]
# Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. Epub 2012 Feb 16. [http://bloodjournal.hematologylibrary.org/content/119/18/4129.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359734/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22343727 PubMed]

==Stanford V {{#subobject:239ec9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2fb53d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/13/5/1080.long Bartlett et al. 1995]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/18/5/972.long Horning et al. 2000 (ECOG E1492)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/27/32/5390.long Hoskin et al. 2009 (UK NCRI ISRCTN 64141244)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_3|ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ Gordon et al. 2013 (ECOG E2496)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ABVD_3|ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
**Patients older than 50: Cycle 3 doses reduced to 4 mg/m<sup>2</sup> per dose
*[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> IV once per day on days 15 & 16 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 8 & 22 
**Patients older than 50: Cycle 3 doses reduced to 1 mg/m<sup>2</sup> per dose
*[[Bleomycin (Blenoxane)]] 5 units/m<sup>2</sup> IV once per day on days 8 & 22
*[[Prednisone (Sterapred)]] as follows:
**Cycles 1 & 2: 40 mg/m<sup>2</sup> PO every other day
**Cycle 3, week 1 (week 9): 40 mg/m<sup>2</sup> PO every other day
**Cycle 3, week 2 (week 10): 30 mg/m<sup>2</sup> PO every other day
**Cycle 3, week 3 (week 11): 20 mg/m<sup>2</sup> PO every other day
**Cycle 3, week 4 (week 12): 10 mg/m<sup>2</sup> PO every other day

====Supportive medications====
*If dose reduction or delay occurred at any time during chemotherapy, [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day x 5 days (starting 48 hours after myelosuppressive chemotherapy) should be given after all subsequent day 1 and 15 doses of chemotherapy. It was not precisely specified when to discontinue filgrastim.
*[[Ranitidine (Zantac)]] 150 mg PO twice per day throughout the course of treatment
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] (160/800 mg) PO twice per day throughout the course of treatment
*[[Acyclovir (Zovirax)]] 200 mg PO three times per day throughout the course of treatment
*[[Ketoconazole (Nizoral)]] 200 mg PO once per day throughout the course of treatment; note: this may be optional--Horning SJ et al. J Clin Oncol (2000) listed this as a prophylactic medication, but Horning SJ et al. J Clin Oncol (2002) did not list this when prophylactic medications were specifically listed.

'''28-day cycle for 3 cycles'''

====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT]] x 36 Gy, started 2 to 4 weeks after chemotherapy is complete and is given to sites of disease greater than or equal to 5 cm and/or to macroscopic nodules in the spleen.

====Dose reductions====
*Doses of doxorubicin, vinblastine, mechlorethamine, and etoposide were reduced to 65% of the original dose if the ANC on the day of treatment was 500 to 1000/uL. If ANC was less than 500/uL on the day of treatment, therapy was delayed for 1 week, and therapy resumed the following week at the dose indicated by the ANC. As noted above, filgrastim was incorporated into all subsequent treatments if there were any dose reductions or delays.

===References===
# Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. [http://jco.ascopubs.org/content/13/5/1080.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7537796 PubMed]
## '''Update:''' Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1;20(3):630-7. [http://jco.ascopubs.org/content/20/3/630.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11821442 PubMed]
# '''ECOG E1492:''' Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. 2000 Mar;18(5):972-80. [http://jco.ascopubs.org/content/18/5/972.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10694546 PubMed]
# Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.907 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16172458 PubMed]
## '''Update:''' Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol. 2011 Nov 10;29(32):4227-33. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.9799 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990405 PubMed]
<!-- Presented at the Annual Meeting of the American Society of Hematology, San Francisco, CA, December, 6-9, 2008; and in part at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June, 7-11, 2005. -->
# '''UK NCRI ISRCTN 64141244:''' Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/32/5390.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19738111 PubMed]
# '''Retrospective:''' Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010 Mar;21(3):574-81. [http://annonc.oxfordjournals.org/content/21/3/574.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19759185 PubMed]
# '''ECOG E2496:''' Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
## '''Subgroup analysis:''' Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]

==VEBEP {{#subobject:d7a2a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VEBEP: '''<u>V</u>'''epesid (Etoposide), '''<u>E</u>'''pirubicin, '''<u>B</u>'''leomycin, '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>P</u>'''rednisolone

===Regimen {{#subobject:91297e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/10526668 Viviani et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
To be completed
====Chemotherapy====
*[[Etoposide (Vepesid)]]
*[[Epirubicin (Ellence)]]
*[[Bleomycin (Blenoxane)]]
*[[Cyclophosphamide (Cytoxan)]]
*[[Prednisolone (Millipred)]]
===References===
# Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am. 1999 Sep-Oct;5(5):275-82. [https://www.ncbi.nlm.nih.gov/pubmed/10526668 PubMed]

=Untreated, pediatric=

==ABVE-PC {{#subobject:c24d93|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVE-PC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>C</u>'''yclophosphamide
===Variant #1, 2 cycles with response adaptation {{#subobject:7fa6ea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/ Friedman et al. 2014 (AHOD0031)]
| style="background-color:#91cf61" |Non-randomized portion of RCT 
|-
|}
''This regimen is intended for pediatric patients, younger than 22 years old. This is the post-amendment dosing described by COG P9425; Friedman et al. 2014 does not contain dosing information.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*Rapid early responders: ABVE-PC x 2 (4 cycles total), then [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy versus [[#Observation|no further treatment]]
*Slow early responders: ABVE-PC x 2 (4 cycles total) versus DECA x 2, then ABVE-PC x 2; then [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy

===Variant #2, 3 cycles with response adaptation {{#subobject:14cd95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ Schwartz et al. 2009 (COG P9425)]
| style="background-color:#91cf61" |Phase II
|-
|}
''This regimen is intended for pediatric patients, younger than 22 years old. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0
====Supportive medications====
*[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 0, 1, 7 (this was a randomization)
*[[Filgrastim (Neupogen)]] 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Rapid early responders: [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy
*Slow early responders: ABVE-PC x 2 (5 cycles total), then [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy

===Variant #3, 4 cycles with response adaptation {{#subobject:17a940|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/ Friedman et al. 2014 (AHOD0031)]
| style="background-color:#91cf61" |Non-randomized portion of RCT 
|-
|}
''This regimen is intended for pediatric patients, younger than 22 years old. This is the post-amendment dosing described by COG P9425; Friedman et al. 2014 does not contain dosing information.''
====Preceding treatment====
*ABVE-PC x 2
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0

'''21-day cycle for 4 cycles, including the first 2 cycles'''
====Subsequent treatment====
*Rapid early responders with CR: [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy versus [[#Observation|no further treatment]]
*Rapid early responders with less than CR: [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy
*Slow early responders: [[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy

===Variant #4, 5 cycles {{#subobject:7e95ea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ Schwartz et al. 2009 (COG P9425)]
| style="background-color:#91cf61" |Phase II
|-
|}
''This regimen is intended for pediatric patients, younger than 22 years old, who are slow early responders. Note that first day of chemotherapy is day 0. Bleomycin and prednisone dosing is post-amendment.''
====Preceding treatment====
*ABVE-PC x 3, with slow early response
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 0 & 1
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV or SC once per day on days 0 & 7 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once per day on days 0 & 7
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 0 to 4
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 0 to 7
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 0
====Supportive medications====
*[[Dexrazoxane (Zinecard)]] 300 mg/m<sup>2</sup> IV once per day on days 0, 1, 7 (this was a randomization)
*[[Filgrastim (Neupogen)]] 5 mcg/kg IV or SC once per day from day 5 until neutrophil recovery (held on day 7)
'''21-day cycle for 5 cycles, including the first 3 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|IFRT consolidation]] x 21 Gy
===References===
# Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 [http://www.bloodjournal.org/content/114/10/2051.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19584400 PubMed]
# Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10;32(32):3651-8. Epub 2014 Oct 13. [http://jco.ascopubs.org/content/32/32/3651.long link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25311218 PubMed]

==OEPA {{#subobject:0e614f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
OEPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin)

===Regimen {{#subobject:25c262|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
''This regimen is meant for boys as it is potentially less gonadotoxic. The original protocol used three doses of dacarbazine per cycle but this was increased to four after a mid-protocol amendment. Patients with early-stage disease only received the OEPA portion, see text for details.''
====Chemotherapy====
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Etoposide (Vepesid)]] 125 mg/m<sup>2</sup> IV once per day on days 2 to 6
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''

====Subsequent treatment====
*Treatment group 2: [[#COPDAC|COPDAC]] x 2
*Treatment group 3: [[#COPDAC|COPDAC]] x 4

===References===
# '''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/23/3680.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20625128 PubMed]

==OPPA {{#subobject:6418c0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
OPPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin)
===Regimen {{#subobject:e17569|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
''This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.''
====Chemotherapy====
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*Treatment group 2: [[#C-MOPP|COPP]] x 2
*Treatment group 3: [[#C-MOPP|COPP]] x 4

===References===
# '''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/23/3680.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20625128 PubMed]

=Untreated, elderly=
==BEACOPP {{#subobject:746746|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Regimen {{#subobject:e65bef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/16/1/124.long Ballova et al. 2005 (GHSG HD9elderly)]
| style="background-color:#1a9851" |Phase III (E)
|[[Hodgkin_lymphoma_-_historical#COPP.2FABVD|COPP/ABVD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note that this is technically "BEACOPP II." The original "BEACOPP I" is detailed in Diehl et al. 1997 but is of historical interest, only.''
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 8 cycles'''

===References===
# '''GHSG HD9elderly:''' Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [http://annonc.oxfordjournals.org/content/16/1/124.long link to original article]'''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15598949 PubMed]

==Brentuximab vedotin monotherapy {{#subobject:dfcf3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, standard-dose {{#subobject:b50c5e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692140/ Forero-Torres et al. 2015]
| style="background-color:#91cf61" |Phase II
| style="background-color:#f7fcfd" |ORR: 92%
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV once on day 1

====Supportive medications====
* "according to institutional standards"

'''21-day cycle for up to 16 cycles, with continuing treatment allowed for those deriving clinical benefit'''

===Variant #2, reduced-dose {{#subobject:d9a488|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692140/ Forero-Torres et al. 2015]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
''This is the starting dose for severe renal impairment (eGFR less than 30 mL/min/1.73m<sup>2</sup>) and also the dose reduction for toxicities. While described as a planned starting dose, no patients in the study actually had severe renal impairment.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once on day 1

====Supportive medications====
* "according to institutional standards"

'''21-day cycle for up to 16 cycles, with continuing treatment allowed for those deriving clinical benefit'''

===References===
<!-- # '''Abstract:''' Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD and Andres Forero-Torres, MD. A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results. ASH 2013 Abstract 4389 [https://ash.confex.com/ash/2013/webprogram/Paper59615.html link to abstract]
## '''Update: Abstract:''' Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD, PhD and Christopher A. Yasenchak, MD. Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study. ASH 2014 Abstract 294 [https://ash.confex.com/ash/2014/webprogram/Paper68173.html link to abstract] -->
# Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798-804. Epub 2015 Sep 16. [http://www.bloodjournal.org/content/126/26/2798.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692140/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26377597 PubMed]

==Brentuximab vedotin & Dacarbazine {{#subobject:c553f3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, standard-dose {{#subobject:4b79fd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/130/26/2829.long Friedberg et al. 2017]
| style="background-color:#91cf61" |Phase II
| style="background-color:#f7fcfd" |ORR: 100%
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV once on day 1
*[[Dacarbazine (DTIC)]] as follows:
**Cycles 1 to 12: 375 mg/m<sup>2</sup> IV once on day 1
**Cycle 13 onwards: no dacarbazine

'''21-day cycle for up to 16 cycles, with continuing treatment allowed for those deriving clinical benefit'''

===Variant #2, reduced-dose {{#subobject:943c66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/130/26/2829.long Friedberg et al. 2017]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
| style="background-color:#f7fcfd" |ORR: 100%
|-
|}
''This is the starting dose for severe renal impairment (eGFR less than 30 mL/min/1.73m<sup>2</sup>). Only 2 patients in the study had severe renal impairment.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once on day 1
*[[Dacarbazine (DTIC)]] as follows:
**Cycles 1 to 12: 262 mg/m<sup>2</sup> IV once on day 1
**Cycle 13 onwards: no dacarbazine

'''21-day cycle for up to 16 cycles, with continuing treatment allowed for those deriving clinical benefit'''
===References===
# Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, Olsen G, Chen R, Fong A, Wang Y, Yasenchak CA. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017 Dec 28;130(26):2829-2837. Epub 2017 Oct 16. [http://www.bloodjournal.org/content/130/26/2829.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29038340 PubMed]

==ChlVPP {{#subobject:6c8a6c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ChlVPP: '''<u>Chl</u>'''lorambucil, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Regimen {{#subobject:f1fd6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/6/2/167.long Anderson 1995]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> (maximum dose of 10 mg/day) PO once per day on days 1 to 14
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> (maximum dose of 10 mg) IV once per day on days 1 & 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> (maximum dose of 150 mg/day) PO once per day on days 1 to 14
*[[Prednisone (Sterapred)]] 40 mg PO once per day on days 1 to 14

'''28-day cycle to complete remission plus 2 cycles; minimum of 6 cycles and maximum of 8 cycles'''

===References===
# '''Retrospective:''' Druker BJ, Rosenthal DS, Canellos GP. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer. 1989 Mar 15;63(6):1060-4. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19890315)63:6%3C1060::AID-CNCR2820630603%3E3.0.CO;2-M/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2917308 PubMed]
# '''Case series:''' Selby P, Patel P, Milan S, Meldrum M, Mansi J, Mbidde E, Brada M, Perren T, Forgeson G, Gore M, Smith I, McElwain T. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer. 1990 Aug;62(2):279-85. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971832/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/2386744 PubMed]
# Anderson JR; The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. Ann Oncol. 1995 Feb;6(2):167-72. [http://annonc.oxfordjournals.org/content/6/2/167.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7786824 PubMed]

==ChlVPP/EVA {{#subobject:8ee324|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ChlVPP/EVA: '''<u>Chl</u>'''lorambucil, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>E</u>'''toposide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin)
===Regimen {{#subobject:48feb0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.9.2379 Radford et al. 1995]
| style="background-color:#1a9851" |Phase III (E)
|[[Hodgkin_lymphoma_-_historical#MVPP|MVPP]]
| style="background-color:#1a9850" |Superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.11.107 Radford et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|VAPEC-B
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 8
*[[Procarbazine (Matulane)]] 90 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisolone (Millipred)]] 50 mg PO once per day on days 1 to 7
*[[Etoposide (Vepesid)]] as follows:
**Cycle 1: 75 mg/m<sup>2</sup> PO once per day on days 1 to 5
**Cycles 2 to 6, if oral mucositis no worse than CTCAE grade 1: 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Vincristine (Oncovin)]] as follows:
**Age 60 to 70: 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
**70 and older: 50% of BSA IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 8

'''28-day cycle for 6 cycles'''

===References===
# Radford JA, Crowther D, Rohatiner AZ, Ryder WD, Gupta RK, Oza A, Deakin DP, Arnott S, Wilkinson PM, James RD, Johnson RJ, Lister TA. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol. 1995 Sep;13(9):2379-85. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.9.2379 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7666097 PubMed]
# Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol. 2002 Jul 1;20(13):2988-94. [http://ascopubs.org/doi/full/10.1200/JCO.2002.11.107 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12089229 PubMed]

==PVAG {{#subobject:e15b65|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PVAG: '''<u>P</u>'''rednisone, '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>G</u>'''emcitabine

===Regimen {{#subobject:773ec7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/118/24/6292.long Böll et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
''This regimen was open to patients with early unfavorable disease, but 93% of patients on study had advanced disease.''
====Chemotherapy====
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 to 8 cycles'''

''Patients with PR at the end of treatment underwent 30 Gy of radiotherapy.''

===References===
# Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8;118(24):6292-8. Epub 2011 Sep 13. [http://www.bloodjournal.org/content/118/24/6292.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21917759 PubMed]

==VEPEMB {{#subobject:2c05e6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VEPEMB: '''<u>V</u>'''inblastine, '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>P</u>'''rocarbazine, '''<u>E</u>'''toposide, '''<u>M</u>'''itoxantrone, '''<u>B</u>'''leomycin
===Regimen {{#subobject:9a2b97|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/15/1/123.long Levis et al. 2004]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13904/full Zallio et al. 2016]
|style="background-color:#1a9851"|Phase III (E)
|ABVD
|style="background-color:#fee08b"|Might have inferior PFS
|-
|}
''Note that this regimen includes prednisone, even though it is not spelled out in the acronym.''
====Chemotherapy====
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> (maximum dose of 10 mg) IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Prednisone (Sterapred)]] 30 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Etoposide (Vepesid)]] 60 mg/m<sup>2</sup> PO once per day on days 15 to 19
*[[Mitoxantrone (Novantrone)]] 6 mg/m<sup>2</sup> IV once on day 15
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once on day 15

'''28-day cycle for 3 to 6 cycles'''
===References===
# Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin's lymphoma patients: results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004 Jan;15(1):123-8. [http://annonc.oxfordjournals.org/content/15/1/123.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14679131 PubMed]
## '''Update:''' Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012 Jun 21;119(25):6005-15. Epub 2012 May 10. [http://www.bloodjournal.org/content/119/25/6005.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22577177 PubMed]
# Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016 Mar;172(6):879-88. Epub 2016 Jan 13. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13904/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26763986 PubMed]

=Consolidation after upfront therapy=
==C-MOPP {{#subobject:034931|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Variant #1, 2 cycles {{#subobject:cfcc4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#OPPA|OPPA]] x 2
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15

'''28-day cycle for 2 cycles'''

===Variant #2, 4 cycles {{#subobject:228db9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#OPPA|OPPA]] x 2
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15

'''28-day cycle for 4 cycles'''
===References===
# '''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/23/3680.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20625128 PubMed]

==COPDAC {{#subobject:195ad7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
COPDAC: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>DAC</u>'''arbazine

===Variant #1, 2 cycles {{#subobject:e9d06d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#OEPA|OEPA]] x 2
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4

'''28-day cycle for 2 cycles'''

===Variant #2, 4 cycles {{#subobject:515d30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/28/23/3680.long Mauz-Körholz et al. 2010 (GPOH-HD-2002)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#OEPA|OEPA]] x 2
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4

'''28-day cycle for 4 cycles'''

===References===
# '''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [http://jco.ascopubs.org/content/28/23/3680.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20625128 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(73)91672-3/fulltext Young et al. 1973]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|Intermittent BCNU
| style="background-color:#ffffbf" |Seems not superior
|-
|Intermittent MOPP
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa022628 Aleman et al. 2003 (EORTC 20884)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Radiation_therapy_2|IFRT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://www.bloodjournal.org/content/104/12/3483.long Straus et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|[[#Radiation_therapy_2|EFRT]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|style="background-color:#fee08b"|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 Radford et al. 2015 (UK NCRI RAPID)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Radiation_therapy_2|IFRT]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|rowspan=2|[https://www.redjournal.org/article/S0360-3016(17)33984-6/fulltext Thomas et al. 2017 (EORTC-GELA H9-F)]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|[[#Radiation_therapy_2|IFRT]] x 20 Gy
| style="background-color:#d3d3d3" |Not reported
|-
|[[#Radiation_therapy_2|IFRT]] x 36 Gy
| style="background-color:#d73027" |Inferior RFS
|-
|}
''No further treatment.''
====Preceding treatment====
*Young et al. 1973: [[#MOPP|MOPP]]
*EORTC 20884: [[#MOPP-ABV_3|MOPP-ABV]] x 6 to 8
*Straus et al. 2004: [[#ABVD_2|ABVD]] x 6
*GHSG HD12: [[#eBEACOPP_2|Escalated BEACOPP]] x 8 versus [[#eBEACOPP_2|Escalated BEACOPP]] x 4, then [[#BEACOPP_2|BEACOPP]] x 4
*UK NCRI RAPID: [[#ABVD|ABVD]] x 3
*EORTC-GELA H9-F: [[#EBVP|EBVP]] x 6
===References===
# Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973 Jun 16;1(7816):1339-43. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(73)91672-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4122739 PubMed]
# '''EORTC 20884:''' Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. [https://www.nejm.org/doi/10.1056/NEJMoa022628 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12802025 PubMed]
# Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9. Epub 2004 Aug 17. [http://www.bloodjournal.org/content/104/12/3483.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15315964 PubMed]
# '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
# '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]
# '''EORTC-GELA H9-F:''' Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. Epub 2017 Oct 27. [https://www.redjournal.org/article/S0360-3016(17)33984-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29229324 PubMed]

==Radiation therapy {{#subobject:b169ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 20 Gy of involved field RT (IFRT) {{#subobject:ded6d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
| style="background-color:#1a9851" |Phase III (E)
|IFRT x 30 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|-
|}
====Preceding treatment====
*GHSG HD10: [[#ABVD|ABVD]] x 2 versus [[#ABVD|ABVD]] x 4
*GHSG HD11: [[#ABVD_2|ABVD]] x 4 versus [[#BEACOPP|BEACOPP]] x 4
====Radiotherapy====
*[[External beam radiotherapy]] 20 Gy

===Variant #2, 21 Gy of IFRT {{#subobject:dfa48c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.12.007 Nachman et al. 2002 (CCG 5942)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Observation|Observation]]
| style="background-color:#1a9850" |Superior EFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ Schwartz et al. 2009 (COG P9425)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/ Friedman et al. 2014 (AHOD0031)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''This regimen is intended for pediatric patients, younger than 22 years old.''
====Preceding treatment====
*CCG 5942: [[#C-MOPP.2FABV|COPP-ABV hybrid]] x 4 or 6 or multi-drug therapy, depending on risk stratification
*COG P9425: [[#ABVE-PC|ABVE-PC]] x 3 to 5
*COG AHOD0031 RERs: [[#ABVE-PC|ABVE-PC]] x 4
*COG AHOD0031 SERs: [[#ABVE-PC|ABVE-PC]] x 4 versus [[#ABVE-PC|ABVE-PC]] x 2, DECA x 2, then [[#ABVE-PC|ABVE-PC]] x 2
====Radiotherapy====
*[[External beam radiotherapy]] 21 Gy in 12 to 14 fractions of 1.50 to 1.75 Gy per fraction

===Variant #3, 24 Gy of IFRT {{#subobject:395388|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa022628 Aleman et al. 2003 (EORTC 20884)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Preceding treatment====
*[[#MOPP-ABV_3|MOPP-ABV]] x 6 to 8, with CR
====Radiotherapy====
*[[External beam radiotherapy]] 24 Gy

===Variant #4, 30 Gy of IFRT {{#subobject:25de6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa022628 Aleman et al. 2003 (EORTC 20884)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.03.023 Engert et al. 2003 (GHSG HD8)]
| style="background-color:#1a9851" |Phase III (E)
|EFRT 30 Gy + 10 Gy boost
| style="background-color:#eeee01" |Equivalent FFTF
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 Engert et al. 2010 (GHSG HD10)]
| style="background-color:#1a9851" |Phase III (C)
|IFRT x 20 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/28/27/4199.long Eich et al. 2010 (GHSG HD11)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|[[Complex_multipart_regimens#GHSG_HD11|See link]]
|-
|[http://jco.ascopubs.org/content/30/9/907.long von Tresckow et al. 2012 (GHSG HD14)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|[[Complex_multipart_regimens#GHSG_HD14|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603439/ Advani et al. 2013 (G4)]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext Behringer et al. 2014 (GHSG HD13)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 Radford et al. 2015 (UK NCRI RAPID)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Observation|No further treatment]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Preceding treatment====
*EORTC 20884: [[#MOPP-ABV_3|MOPP-ABV]] x 6 to 8, with PR
*GHSG HD8: [[Hodgkin_lymphoma_-_historical#COPP.2FABVD|COPP/ABVD]] x 4
*GHSG HD10: [[#ABVD|ABVD]] x 2 versus [[#ABVD|ABVD]] x 4
*GHSG HD11: [[#ABVD_2|ABVD]] x 4 versus [[#BEACOPP|BEACOPP]] x 4
*GHSG HD14: [[#ABVD_2|ABVD]] x 4 versus [[#ABVD_2|ABVD]] x 2, then [[#eBEACOPP|Escalated BEACOPP]] x 2
*G4: [[#Stanford_V|Stanford V]] x 8 wk
*GHSG HD13: [[#ABVD|ABVD]] x 2
*UK NCRI RAPID: [[#ABVD|ABVD]] x 3
====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy

===Variant #5, 30 Gy of involved site RT (ISRT) {{#subobject:d2780e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/32/4234.long Borchmann et al. 2011 (GHSG HD12)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|style="background-color:#d9ef8b"|[[Complex_multipart_regimens#GHSG_HD12|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025897/ Kumar et al. 2016]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*GHSG HD12: [[#eBEACOPP_2|Escalated BEACOPP]] x 8 versus [[#eBEACOPP_2|Escalated BEACOPP]] x 4, then [[#BEACOPP_2|BEACOPP]] x 4
*Kumar et al. 2016: [[#A.2BAVD|BV + AVD]] x 4
====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy

===Variant #6, 30 Gy of involved node RT (INRT) + 6 Gy boost {{#subobject:465f05|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|[[Complex_multipart_regimens#EORTC.2FLYSA.2FFIL_H10|See link]]
|-
|}
====Preceding treatment====
*EORTC H10 F: [[#ABVD|ABVD]] x 3
*EORTC H10 U: [[#ABVD|ABVD]] x 4

====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy (+ 6 Gy boost)

===Variant #7, 30 Gy of extended-field RT (EFRT) + 10 Gy boost {{#subobject:54497b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.03.023 Engert et al. 2003 (GHSG HD8)]
| style="background-color:#1a9851" |Phase III (C)
|IFRT 30 Gy + 10 Gy boost
| style="background-color:#eeee01" |Equivalent FFTF
|-
|[http://jco.ascopubs.org/content/25/23/3495.long Engert et al. 2007 (GHSG HD7)]
| style="background-color:#1a9851" |Phase III (E)
|EFRT
| style="background-color:#1a9850" |Superior FFTF
|-
|}
====Preceding treatment====
*GHSG HD8: [[Hodgkin_lymphoma_-_historical#COPP.2FABVD|COPP/ABVD]] x 4
*GHSG HD7: [[#ABVD|ABVD]] x 2
====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy + 10 Gy to the involved field

===Variant #8, 35 Gy of subtotal nodal irradiation (STNI) {{#subobject:5a41f1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.09.085 Meyer et al. 2005 (NCIC CTG/ECOG HD.6)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NCIC_CTG.2FECOG_HD.6|See link]]
|[[Complex_multipart_regimens#NCIC_CTG.2FECOG_HD.6|See link]]
|-
|}
''Note: [[#Radiation_therapy|see link]] for use of STNI as definitive therapy.''
====Preceding treatment====
*Unfavorable risk: [[#ABVD|ABVD]] x 2
====Radiotherapy====
*[[External beam radiotherapy]] 35 Gy in 20 fractions

===Variant #9, 36 Gy of IFRT {{#subobject:9f26c9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|STNI x 36 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ Gordon et al. 2012 (ECOG E2496)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*Bonadonna et al. 2004: [[#ABVD|ABVD]] x 4, with CR
*EORTC-GELA H8-F: [[#MOPP-ABV|MOPP-ABV]] x 3, with CR
*EORTC-GELA H8-U: [[#MOPP-ABV_2|MOPP-ABV]] x 4 versus [[#MOPP-ABV_2|MOPP-ABV]] x 6, with CR
*ECOG E2496: [[#ABVD_2|ABVD]] x 6 to 8 versus [[#Stanford_V_2|Stanford V]] x 12 wk
====Radiotherapy====
*[[External beam radiotherapy]] 36 Gy in 18 fractions of 2.00 Gy per fraction

===Variant #10, 36 Gy of STNI {{#subobject:0518ef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|IFRT x 36 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[#ABVD|ABVD]] x 4, with CR
====Radiotherapy====
*[[External beam radiotherapy]] 36 Gy to involved sites, 30.6 Gy to uninvolved sites

===Variant #11, 36 Gy of STNI + 4 Gy boost {{#subobject:6fdd53|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|-
|}
====Preceding treatment====
*[[#MOPP-ABV_2|MOPP-ABV]] x 4

====Radiotherapy====
*[[External beam radiotherapy]] 36 Gy in 18 fractions of 2.00 Gy per fraction, with 4 Gy boost to involved fields

===Variant #12, 40 Gy of IFRT {{#subobject:19c9cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|STNI x 40 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-F)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-F|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064601 Fermé et al. 2007 (EORTC-GELA H8-U)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|[[Complex_multipart_regimens#EORTC-GELA_H8-U|See link]]
|-
|}
====Preceding treatment====
*Bonadonna et al. 2004: [[#ABVD|ABVD]] x 4, with CRu or PR
*EORTC-GELA H8-F: [[#MOPP-ABV|MOPP-ABV]] x 3, with PR
*EORTC-GELA H8-U: [[#MOPP-ABV_2|MOPP-ABV]] x 4 versus [[#MOPP-ABV_2|MOPP-ABV]] x 6, with PR
====Radiotherapy====
*[[External beam radiotherapy]] 40 Gy in 20 fractions of 2.00 Gy per fraction

===Variant #13, 40 Gy of STNI {{#subobject:2de34b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/14/2835.long Bonadonna et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|IFRT x 40 Gy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[#ABVD|ABVD]] x 4, with CRu or PR
====Radiotherapy====
*[[External beam radiotherapy]] 40 Gy to involved sites, 30.6 Gy to uninvolved sites

===References===
# Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JH, Le Fur R et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993 Nov;11(11):2258-72. [http://jco.ascopubs.org/content/11/11/2258.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7693881 PubMed]
# '''CCG 5942:''' Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K; Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002 Sep 15;20(18):3765-71. [http://ascopubs.org/doi/full/10.1200/JCO.2002.12.007 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12228196 PubMed]
## '''Update:''' Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, Sposto R, Kadin ME, Hutchinson RJ, Nachman J. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol. 2012 Sep 10;30(26):3174-80. Epub 2012 May 29. [http://ascopubs.org/doi/full/10.1200/JCO.2011.41.1819 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434976/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22649136 PubMed]
# '''EORTC 20884:''' Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. [https://www.nejm.org/doi/10.1056/NEJMoa022628 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12802025 PubMed]
# '''GHSG HD8:''' Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. [http://ascopubs.org/doi/full/10.1200/JCO.2003.03.023 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12913100 PubMed]
## '''Update:''' Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A; German Hodgkin Study Group (GHSG). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol. 2012 Nov;23(11):2953-9. Epub 2012 Jul 5. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mds110 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22767583 PubMed]
## '''Update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
# Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41. [http://jco.ascopubs.org/content/22/14/2835.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15199092 PubMed]
# '''NCIC CTG/ECOG HD.6:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18. [http://ascopubs.org/doi/10.1200/JCO.2005.09.085 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15837968 PubMed]
## '''Update:''' Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408. Epub 2011 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111961 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932020/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149921 PubMed]
# '''GHSG HD7:''' Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10;25(23):3495-502. [http://jco.ascopubs.org/content/25/23/3495.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17606976 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
# '''EORTC-GELA H8-U:''' Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa064601 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/17989384 PubMed]
# Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 3;114(10):2051-9. Epub 2009 Jul 7. Erratum: in Blood 2016 128:605 [http://www.bloodjournal.org/content/114/10/2051.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744567/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19584400 PubMed]
# '''GHSG HD10:''' Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa1000067 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20818855 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.4181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23509310 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
# Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16. [http://jco.ascopubs.org/content/28/27/4199.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20713848 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.4181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23509310 PubMed]
## '''Pooled update:''' Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.9410 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28418763 PubMed]
# '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [http://jco.ascopubs.org/content/29/32/4234.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21990399 PubMed]
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30290903 PubMed]
<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL. -->
# '''GHSG HD14:''' von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13. Epub 2012 Jan 23. [http://jco.ascopubs.org/content/30/9/907.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22271480 PubMed]
# '''G4:''' Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013 Apr;24(4):1044-8. Epub 2012 Nov 7. '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603439/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23136225 PubMed]
# '''ECOG E2496:''' Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/6/684.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574266/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182987 PubMed]
## '''Subgroup analysis:''' Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76-86. Epub 2013 Jan 29. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23356491 PubMed]
## '''Subgroup analysis:''' Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42. Epub 2015 Apr 20. [http://jco.ascopubs.org/content/33/17/1936.full link to original article] '''contains limited protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25897153 PubMed]
<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''EORTC/LYSA/FIL H10:''' Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
## '''Update:''' André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14. [http://ascopubs.org/doi/full/10.1200/JCO.2016.68.6394 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28291393 PubMed]
# '''COG AHOD0031:''' Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10;32(32):3651-8. Epub 2014 Oct 13. [http://jco.ascopubs.org/content/32/32/3651.long link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220044/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25311218 PubMed]
# '''GHSG HD13:''' Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61469-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25539730 PubMed]
## '''Pooled sub-group analysis:''' Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92. Epub 2016 Feb 1.[http://www.bloodjournal.org/content/127/18/2189.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26834240 PubMed]
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
# '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]
# Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458-64. Epub 2016 Jul 25. [http://www.bloodjournal.org/content/128/11/1458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025897/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27458003 PubMed]

=Relapsed or refractory, all lines of therapy=
==ABVD {{#subobject:2f51d3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Regimen {{#subobject:230cf5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 Radford et al. 2015 (UK NCRI RAPID)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#ABVD|ABVD]] x 3, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 3 to 5 refractory disease
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Dacarbazine (DTIC)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for 1 cycle'''
====Subsequent treatment====
*[[#Radiation_therapy_3|IFRT]]

===References===
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
# '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]

==BEACOPP-14 {{#subobject:cb9545|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP-14: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>14</u>'''-day course
===Regimen {{#subobject:b5cf66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ Johnson et al. 2016 (RATHL)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#ABVD_3|ABVD]] x 2, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 4 or 5 refractory disease
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisolone (Millipred)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 7

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] 263/300 mcg SC once per day on days 9 to 13 OR
*[[Pegfilgrastim (Neulasta)]] (dose/day not specified) SC once

'''14-day cycle for 4 to 6 cycles'''

===References===
# '''RATHL:''' Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [https://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]

==BEACOPP {{#subobject:bdb2d4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEACOPP: '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
<br>BEACOPP<sub>baseline</sub>
===Regimen {{#subobject:7e0f6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 Gallamini et al. 2018 (GITIL/FIL HD 0607)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#eBEACOPP_3|eBEACOPP]] x 4
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 650 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 4 cycles'''

===References===
# '''GITIL/FIL HD 0607:''' Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018 Feb 10;36(5):454-462. Epub 2018 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29360414 PubMed]

==eBEACOPP {{#subobject:ca99d7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
eBEACOPP: '''<u>e</u>'''scalated '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone
===Variant #1, 2 cycles {{#subobject:b24244|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: dosing is not described in the paper; this is the standard escalated BEACOPP as described elsewhere.''
====Preceding treatment====
*EORTC H10 F: [[#ABVD|ABVD]] x 2, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 3 to 5 refractory disease
*EORTC H10 U: [[#ABVD_2|ABVD]] x 2, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 3 to 5 refractory disease
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_3|INRT]]

===Variant #2, 3 cycles with response adaptation {{#subobject:f6f9f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ Johnson et al. 2016 (RATHL)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#ABVD_3|ABVD]] x 2, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 4 or 5 refractory disease
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1250 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisolone (Millipred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] 263/300 mcg SC once per day on days 9 to 13 OR
*[[Pegfilgrastim (Neulasta)]] (dose/day not specified) SC once

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Second interim PET-CT negative: eBEACOPP x 1 (4 total)

===Variant #3, 4 cycles {{#subobject:5e3e1f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 Gallamini et al. 2018 (GITIL/FIL HD 0607)]
| style="background-color:#1a9851" |Phase III (C)
|R-BEACOPP
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: patients in '''GHSG HD18''' enrolled after June 2011 would receive a total of 6 cycles.''
====Preceding treatment====
*GHSG HD18: [[#eBEACOPP_2|eBEACOPP]] x 2, with positive interim PET-CT
*GITIL/FIL HD 0607: [[#ABVD_3|ABVD]] x 2, with positive interim PET-CT
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 to 1250 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 mcg SC once per day, starting day 8, continues until ANC greater than 1000/uL

'''21-day cycle for 4 cycles (see note)'''
====Subsequent treatment====
*GITIL/FIL HD 0607, negative interim PET-CT: [[#BEACOPP_4|BEACOPP (baseline)]] x 4
*GITIL/FIL HD 0607, positive interim PET-CT: [[#DHAP|DHAP salvage]]

===Variant #4, 6 cycles {{#subobject:056e0a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/ Press et al. 2016 (SWOG S0816)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext Borchmann et al. 2017 (GHSG HD18)]
| style="background-color:#1a9851" |Phase III (C)
|R-BEACOPP<sub>escalated</sub>
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: patients in '''GHSG HD18''' enrolled prior to June 2011 would receive a total of 8 cycles.''
====Preceding treatment====
*SWOG S0816: [[#ABVD_3|ABVD]] x 2, with interim PET-CT showing [[#Deauville_criteria_.282010.29|Deauville score]] 4 or 5 refractory disease
*GHSG HD18: [[#eBEACOPP_2|eBEACOPP]] x 2, with positive interim PET-CT
====Chemotherapy====
*[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once on day 8
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Doxorubicin (Adriamycin)]] 35 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 8
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''21-day cycle for 6 cycles'''

===References===
<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''EORTC/LYSA/FIL H10:''' Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
## '''Update:''' André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14. [http://ascopubs.org/doi/full/10.1200/JCO.2016.68.6394 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28291393 PubMed]
# '''SWOG S0816:''' Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. [http://jco.ascopubs.org/content/34/17/2020.full link to original article] '''refers to original protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27069074 PubMed]
# '''RATHL:''' Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. [https://www.nejm.org/doi/full/10.1056/NEJMoa1510093 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1510093/suppl_file/nejmoa1510093_protocol.pdf link to protocol] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27332902 PubMed]
# '''GHSG HD18:''' Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017 Apr;18(4):454-463. Epub 2017 Feb 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30103-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28236583 PubMed]
## '''Update:''' Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017 Dec 23;390(10114):2790-2802. Epub 2017 Oct 20. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32134-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29061295 PubMed]
# '''GITIL/FIL HD 0607:''' Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018 Feb 10;36(5):454-462. Epub 2018 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.2543 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29360414 PubMed]

==BeGEV {{#subobject:178f18|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BeGEV: '''<u>Be</u>'''ndamustine, '''<u>GE</u>'''mcitabine, '''<u>V</u>'''inorelbine
===Regimen {{#subobject:f4d976|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/34/27/3293.full Santoro et al. 2016 (ONC-2010-002)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 2 & 3
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 4

====Supportive medications====
*Growth factor support
*PJP prophylaxis and antiemetics in accordance with institutional guidelines

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients with PR/CR: [[#BEAM.2C_then_auto_HSCT|BEAM, then autologous hematopoietic cell transplant]] or FEAM, then autologous hematopoietic cell transplant

===References===
# '''ONC-2010-002:''' Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016 Sep 20;34(27):3293-9. Epub 2016 Jul 5. [http://jco.ascopubs.org/content/34/27/3293.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27382096 PubMed]

==Bendamustine monotherapy {{#subobject:a6466b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:90efdf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862960/ Moskowitz et al. 2013]
| style="background-color:#91cf61" |Phase II
| style="background-color:#9ebcda" |ORR: 53%
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2

====Supportive medications====
*One of the following used each cycle; paper does not specify exact timing/duration:
**[[Filgrastim (Neupogen)]]
**[[Pegfilgrastim (Neulasta)]] 
*PCP prophylaxis and antiemetics according to institutional guidelines

'''28-day cycle for up to 6 cycles'''

===References===
# Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013 Feb 1;31(4):456-60. Epub 2012 Dec 17. [http://jco.ascopubs.org/content/31/4/456.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862960/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23248254 PubMed]

==Brentuximab vedotin monotherapy {{#subobject:c7e71|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, q3wk cycle x 4 {{#subobject:30ca4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639410/ Chen et al. 2015]
| style="background-color:#91cf61" |Phase II
| style="background-color:#bfd3e6" |ORR: 68%
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV over 30 minutes once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Auto HSCT, with choice of regimen left to discretion of treating physician

===Variant #2, q3wk, indefinite {{#subobject:ffbe2c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1002965 Younes et al. 2010 (SG035-0001)]
| style="background-color:#ffffbe" |Phase 1
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646316/ Younes et al. 2012 (SG035-0003)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#bfd3e6" |ORR: 75% (95% CI, 65-83)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731651/ Gopal et al. 2012 (SGN35-006)]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#8c96c6" |ORR: 50%
|-
|}
''Note: '''SGN35-006''' is a re-treatment trial; all patients were previously exposed to brentuximab vedotin. Patients who had received the 1.2 mg/kg dose on a prior trial also received that dose at re-treatment.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV over 30 minutes once on day 1

====Supportive medications====
*Rothe et al. 2012: "no premedications were administered"
 
'''21-day cycle for up to 16 infusions (SG035-0003) or indefinitely (SGO35-0001 & SGN35-006)'''

===Variant #3, 3 out of 4 weeks {{#subobject:668c79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70013-6/fulltext Moskowitz et al. 2015 (MSK 11-142)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#8c6bb1" |PET-negative rate: 27% (95% CI, 13-40)
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.2 mg/kg IV once per day on days 1, 8, 15

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*PET-negative patients (a Deauville score of 1 or 2): Autologous hematopoietic cell transplant with [[#BEAM.2C_then_auto_HSCT|BEAM]], CBV, or high dose chemoradiotherapy
*PET-positive patients: Two cycles of [[#ICE|augmented ICE]] prior to transplant

===References===
# '''Phase 1:''' Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812-21. [https://www.nejm.org/doi/10.1056/NEJMoa1002965 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21047225 PubMed]
<!-- Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL; the 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL; 11th International Conference on Malignant Lymphoma, June 15-18, 2011, Lugano, Switzerland. -->
# '''SG035-0003:''' Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183-9. Epub 2012 Mar 26. [http://jco.ascopubs.org/content/30/18/2183.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646316/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22454421 PubMed]
<!-- ## '''Update: Abstract:''' Robert Chen, Scott E. Smith, Stephen M Ansell, Joseph D Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dirk Huebner, Eric L. Sievers, Anas Younes. Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood Nov 2013,122(21)4382. [http://bloodjournal.hematologylibrary.org/content/122/21/4382 link to abstract]
## '''Update: Abstract:''' The 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-20, 2013 -->
## '''Update:''' Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19;125(8):1236-43. Epub 2014 Dec 22. [http://www.bloodjournal.org/content/125/8/1236 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335079/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25533035 PubMed]
## '''Update:''' Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 Sep 22;128(12):1562-6. Epub 2016 Jul 18. [http://www.bloodjournal.org/content/128/12/1562.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034737/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27432875 PubMed]
<!-- Presented in part as an oral presentation at the 37th annual meeting of the European Group for Blood and Marrow Transplantation, April 5, 2011, Paris, France. -->
# '''SGN35-006:''' Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560-8. Epub 2012 Apr 17. [http://bloodjournal.hematologylibrary.org/content/120/3/560.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731651/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22510871 PubMed]
## '''Update:''' Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 Mar 19;7:24. [http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-7-24 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994656/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24642247 PubMed]
# '''Retrospective:''' Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, Bangard C, Böll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012 Aug 16;120(7):1470-2. Epub 2012 Jul 11. [http://bloodjournal.hematologylibrary.org/content/120/7/1470.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22786877 PubMed]
# '''Retrospective:''' Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014 Oct;55(10):2328-34. Epub 2014 Feb 24. [http://www.tandfonline.com/doi/full/10.3109/10428194.2013.876496 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24359243 PubMed]
# '''Case series:''' Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015 Mar;56(3):703-10. Epub 2015 Jan 21 [https://www.tandfonline.com/doi/full/10.3109/10428194.2014.930852 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24913507 PubMed]
<!-- # '''Abstract:''' Heiko Schoder, John F. Gerecitano, Paul Hamlin, Steven M. Horwitz, Matthew J Matasar, Vahakn S Keskinyan, Susan McCall, Ariela Noy, M. Lia Palomba, Carol S. Portlock, David J Straus, Joachim Yahalom, Anas Younes, Andrew D Zelenetz, Craig H. Moskowitz. FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma. Blood Nov 2013,122(21)2099 [http://bloodjournal.hematologylibrary.org/content/122/21/2099 link to abstract] -->
# '''MSK 11-142:''' Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. Epub 2015 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70013-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25683846 PubMed]
# Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-40. Epub 2015 Jul 26. [http://www.bbmt.org/article/S1083-8791(15)00495-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639410/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26211987 PubMed]
## '''Subgroup analysis:''' Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018 Mar 1;29(3):724-730. [https://academic.oup.com/annonc/article/29/3/724/4767824 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889038/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29272364 PubMed]

==Brentuximab vedotin & Nivolumab {{#subobject:ca85f1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2db6df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/131/11/1183.long Herrera et al. 2017 (SGN35-025)]
| style="background-color:#91cf61" |Phase I/II
| style="background-color:#e0ecf4" |ORR: 82% (95% CI, 70-91)
|-
|}
''Note: this is the dosing used for all patients in the trial, per the manuscript.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV over 30 minutes once on day 1
*[[Nivolumab (Opdivo)]] as follows:
**Cycle 1: 3 mg/kg IV over 60 minutes once on day 8
**Cycles 2 to 4: 3 mg/kg IV over 60 minutes once on day 1, '''given at least 30 minutes after brentuximab vedotin'''

'''21-day cycle for up to 4 cycles'''
====Subsequent treatment====
*At the discretion of the treating physician
===References===
# '''SGN35-025:''' Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018 Mar 15;131(11):1183-1194. Epub 2017 Dec 11. [http://www.bloodjournal.org/content/131/11/1183.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29229594 PubMed]

==BVB {{#subobject:a6466b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BVB: '''<u>B</u>'''rentuximab '''<u>V</u>'''edotin & '''<u>B</u>'''endamustine
===Regimen {{#subobject:90efdf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/132/1/40.long LaCasce et al. 2018 (SGN35-016)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV once on day 1
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycle for up to 6 cycles'''
====Subsequent treatment====
*Optional autologous HSCT any time after cycle 2; most received [[#BEAM.2C_then_auto_HSCT|BEAM, then auto HSCT]]
*Optional [[#Brentuximab_vedotin_monotherapy_3|brentuximab vedotin maintenance]] for a maximum of 16 cycles

===References===
<!-- #'''Abstract:''' LaCasce A, Bociek RG, Matous J, et al. Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Presented at: 2014 ASH Annual Meeting; December 6-9, 2014; San Francisco, CA. Abstract 293 [http://www.bloodjournal.org/content/124/21/293 link to abstract]. -->
# '''SGN35-016:''' LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5;132(1):40-48. Epub 2018 Apr 27. [http://www.bloodjournal.org/content/132/1/40.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29703778 PubMed]

==DexaBEAM {{#subobject:25ea1a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DexaBEAM: '''<u>Dexa</u>'''methasone, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Variant #1, 2 cycles with standard-dose etoposide {{#subobject:00ef8f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/pdf/10.1200/JCO.1994.12.3.580 Pfreundschuh et al. 1994]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 2
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 4 to 7
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7
*[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] starting on day 8, continued until WBC count recovery or the last day of stem-cell harvesting

'''28-day cycle for 2 cycles'''
====Subsequent treatment====
*Chemosensitive disease: DexaBEAM x 2 to 3 more cycles or [[#CBV.2C_then_auto_HSCT|CBV, then autologous HSCT]]

===Variant #2, 2 cycles with higher-dose etoposide {{#subobject:00ef8f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08938-9/fulltext Schmitz et al. 2002 (GHSG HD-R1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: the dose of etoposide was reduced per a mid-protocol amendment.''
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 2
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV once per day on days 4 to 7
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7
*[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] starting on day 8, continued until WBC count recovery or the last day of stem-cell harvesting

'''2 cycles (length not specified)'''
====Subsequent treatment====
*Chemosensitive disease: DexaBEAM x 2 versus [[#BEAM.2C_then_auto_HSCT|BEAM, then autologous HSCT]]

===Variant #3, 4 cycles total with higher-dose etoposide {{#subobject:fe391a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08938-9/fulltext Schmitz et al. 2002 (GHSG HD-R1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#BEAM.2C_then_auto_HSCT|BEAM, then autologous HSCT]]
| style="background-color:#fc8d59" |Seems to have inferior FFTF
|-
|}
====Preceding treatment====
*DexaBEAM x 2
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 2
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV once per day on days 4 to 7
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7
*[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3

====Supportive medications====
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] starting on day 8, continued until WBC count recovery or the last day of stem-cell harvesting

'''2 cycles (length not specified) for a total of 4 cycles'''
===References===
# Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994 Mar;12(3):580-6. [http://ascopubs.org/doi/pdf/10.1200/JCO.1994.12.3.580 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8120557 PubMed]
# '''GHSG HD-R1:''' Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08938-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12086759 PubMed]

==DHAP {{#subobject:ad82a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DHAP: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:75da55|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/71/1/117 Velasquez et al. 1988]
| style="background-color:#91cf61" |Phase II
|-
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.5771 Josting et al. 2010 (GHSG HD-R2)
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269494/ Sureda et al. 2011 (HDR-ALLO)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 40 mg IV or PO over 15 minutes once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] as follows:
**70 and younger: 2000 mg/m<sup>2</sup> IV given over 3 hours every 12 hours x 2 doses on day 2
**>70 years old: 1000 mg/m<sup>2</sup> IV given over 3 hours every 12 hours x 2 doses on day 2
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*Normal saline with mannitol 50 g/L given at 250 mL/H x 36 hours, starting 6 hours before [[Cisplatin (Platinol)]] infusion was started

'''21 to 28-day cycles (depending on degree of myelosuppression)'''
====Subsequent treatment====
*Velasquez et al. 1988: 6 to 10 cycles, with therapy given 4 cycles beyond the maximum antitumor effect
*GHSG HD-R2: BEAM with auto HSCT versus SHDCT, then BEAM with auto HSCT
*Sureda et al. 2011 gave 2 cycles, with responders proceeding to [[#Allogeneic_hematopoietic_stem_cell_transplant|Flu-Mel RIC-allo HSCT]]

====Dose modifications====
*Aside from the table below (from Velasquez et al. 1988), there were no specific cutoff criteria about dose modifications or delays of treatment. 
{| class="wikitable" style="width: 100%; text-align:center;" 
! colspan="3" |Dose modifications
|-
! align="left" | Event
!Cytarabine (Cytosar)
!Cisplatin (Platinol)
|-
| align="left" | ANC less than 200/uL
|1000 mg/m<sup>2</sup> x 2 doses
|100 mg/m<sup>2</sup>
|-
| align="left" | Platelets less than 20 x 10<sup>9</sup>/L
|1000 mg/m<sup>2</sup> x 2 doses
|100 mg/m<sup>2</sup>
|-
| align="left" | Sepsis associated with neutropenia
|500 mg/m<sup>2</sup> x 1 dose
|100 mg/m<sup>2</sup>
|-
| align="left" | Cr 1.5 to 2.0
| -
|75 mg/m<sup>2</sup>
|-
| align="left" | Cr 2.1-3.0
| -
|50 mg/m<sup>2</sup>
|-
|}

===References===
# Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22. [http://www.bloodjournal.org/content/71/1/117 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3334893 PubMed]
# '''GHSG HD-R2:''' Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010 Dec 1;28(34):5074-80. Epub 2010 Oct 25. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.5771 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20975066 PubMed]
# '''HDR-ALLO:''' Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma: results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012 Feb;97(2):310-7. Epub 2011 Oct 11. [http://www.haematologica.org/content/97/2/310.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269494/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21993674 PubMed]

==DHAP - time intensified {{#subobject:8875a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DHAP - time intensified: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:2255aa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/13/10/1628.long Josting et al. 2002]
| style="background-color:#91cf61" |Phase II
|-
|}

''This was used as a salvage regimen for relapsed/refractory Hodgkin Lymphoma in patients who were planned for high-dose chemotherapy (HDCT) and autologous hematopoietic cell transplantation.''
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV given over 3 hours every 12 hours x 2 doses on day 2
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*Hydration at 250 mL/H started 2 to 6 hours before [[Cisplatin (Platinol)]] infusion was started
*Prednisolone acetate 1% eyedrops 1 drop to both eyes TID; start 12 hours before start of [[Cytarabine (Cytosar)]] and continued for 2 days after cytarabine administration complete
*[[Ondansetron (Zofran)]] 8 mg IV once per day on days 1 & 2
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC per day, start 24 hours after last dose of [[Cytarabine (Cytosar)]] and continue until ANC greater than 2500/uL for 3 days 

'''Variable number of days between cycles depending on count recovery for 2 cycles''' Median time between cycle 1 and 2 was 16 days. The paper did not definitively specify what criteria needed to be fulfilled before cycle 2 was given. Baseline eligibility criteria for the study included WBC count greater than 3.5 x 10<sup>9</sup>/L, Hb greater than or equal to 8 g/dL, platelets greater than or equal to 100 x 10<sup>9</sup>/L.

===References===
# Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002 Oct;13(10):1628-35. [http://annonc.oxfordjournals.org/content/13/10/1628.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377653 PubMed]

==ESHAP {{#subobject:1dd425|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ESHAP: '''<u>E</u>'''toposide, '''<u>S</u>'''olumedrol (Methylprednisolone) '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)

===Regimen {{#subobject:2ed80b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/10/5/593.long Aparicio et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note that the authors state that they used the protocol defined by [http://jco.ascopubs.org/content/12/6/1169.long Velasquez et al. 1994]. However, there are some differences in the text describing methylprednisolone dosing from that in the original article. Below are the doses reported in the original article, with the addition of G-CSF as specified in Aparicio et al. 1999.''
====Chemotherapy====
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
*[[Methylprednisolone (Solumedrol)]] 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 5
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>) 

====Supportive medications====
*At least 1 liter normal saline with 25 to 50 g [[Mannitol]] once per day throughout chemotherapy
*[[Metoclopramide (Reglan)]] 0.5 to 1 mg/kg (route not specified) "given regularly"
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 6 to 18

'''21- to 28-day cycle for 3 cycles; see below'''

====Subsequent treatment====
*Transplant eligible patients with "responsive disease" after 3 cycles: CBV with auto HSCT
*Transplant ineligible patients with "responsive disease" received 3 more cycles of ESHAP (6 total)

===References===
# Aparicio J, Segura A, Garcerá S, Oltra A, Santaballa A, Yuste A, Pastor M. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999 May;10(5):593-5. [http://annonc.oxfordjournals.org/content/10/5/593.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10416011 PubMed]

==Everolimus monotherapy {{#subobject:366e6b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:67eaa8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420736/ Johnston et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day on an empty stomach 

====Supportive medications====
*"Patients could receive white blood cell growth factors if neutropenia developed. Erythropoietin treatment for anemia was permitted."

'''28-day cycles'''

===References===
# Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320-4. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.21664/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420736/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20229590 PubMed]

==GCD {{#subobject:8d6834|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GCD: '''<u>G</u>'''emcitabine, '''<u>C</u>'''arboplatin, '''<u>D</u>'''examethasone

===Regimen {{#subobject:fff2d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018339/ Gopal et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive medications====
*Growth factor support and antibiotic prophylaxis used is at the discretion of the treating physician.

'''21-day cycle for up to 4 cycles'''

====Dose modifications====
*[[Gemcitabine (Gemzar)]]:
**If on day 8, platelets are 50 to 100 x 10<sup>9</sup>/L or ANC 500 to 1000/uL: reduce dose by 25% for that dose only.
**If on day 8, platelets are less than 50 x 10<sup>9</sup>/L or ANC less than 500/uL: No day 8 dose given.
**Subsequent cycles would be given at full dose if patients had platelets greater than or equal to 50 x 10<sup>9</sup>/L or ANC greater than or equal to 1000/uL.
**If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.

===References===
# Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010 Aug;51(8):1523-9. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018339/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20578815 PubMed]

==GCD-R {{#subobject:71f781|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GCD-R: '''<u>G</u>'''emcitabine, '''<u>C</u>'''arboplatin, '''<u>D</u>'''examethasone, '''<u>R</u>'''ituximab

===Regimen {{#subobject:dcc6bd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018339/ Gopal et al. 2010]
| style="background-color:#91cf61" |Phase II
|-
|}
''Only used when disease is CD20+.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> slow IV infusion once on day 8

====Supportive medications====
*Growth factor support and antibiotic prophylaxis used is at the discretion of the treating physician.

'''21-day cycle for up to 4 cycles'''

====Dose modifications====
*[[Gemcitabine (Gemzar)]]:
**If on day 8, platelets are 50 to 100 x 10<sup>9</sup>/L or ANC 500 to 1000/uL: reduce dose by 25% for that dose only.
**If on day 8, platelets are less than 50 x 10<sup>9</sup>/L or ANC less than 500/uL: No day 8 dose given.
**Subsequent cycles would be given at full dose if patients had platelets greater than or equal to 50 x 10<sup>9</sup>/L or ANC greater than or equal to 1000/uL.
**If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.

===References===
# Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE, Smith JC, Pagel JM. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010 Aug;51(8):1523-9. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018339/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20578815 PubMed]

==Gemcitabine monotherapy {{#subobject:df3421|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:4d3a21|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/18/13/2615.long Santoro et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] as follows:
**Cycle 1: 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
**Subsequent cycles (if no hematologic or nonhematologic toxicities): 1500 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000 Jul;18(13):2615-9. [http://jco.ascopubs.org/content/18/13/2615.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10893294 PubMed]

==Gemcitabine & Rituximab {{#subobject:1568f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:3f819c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23237/full Oki et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}

''Patients had received at least 2 prior chemotherapy regimens.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for the first 2 cycles (6 doses total)

'''21-day cycle for up to 6 cycles'''

====Dose modifications====
*[[Gemcitabine (Gemzar)]]:
**'''Dose level 0:''' 1250 mg/m<sup>2</sup>
**'''Dose level -1:''' 1000 mg/m<sup>2</sup>
**'''Dose level -2:''' 750 mg/m<sup>2</sup>
**If ANC less than or equal to 1000/uL on day 1 of the following cycle, delay until count recovery
**If ANC remains less than or equal to 1000/uL for one week or longer, reduce dose by one level
**If platelets less than or equal to 50 x 10<sup>9</sup>/L on day 1 of the following cycle, delay until count recovery AND reduce dose by one level

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 10–13, 2005. -->
# Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15;112(4):831-6. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23237/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18085611 PubMed]

==GVD {{#subobject:3fe688|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GVD: '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine, '''<u>D</u>'''oxil (Liposomal doxorubicin)
===Variant #1, transplant-naive {{#subobject:9d8319|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/6/1071.long Bartlett et al. 2007 (CALGB 59804)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Note: this corresponds to dose level 1 used in the dose-finding portion of the protocol; see paper for further details.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8 '''second medication given'''
**If on day 8, platelets are 50 to 100 x 10<sup>9</sup>/L or ANC 500 to 1000/uL: reduce dose by 25% for that dose only.
**If on day 8, platelets are less than 50 x 10<sup>9</sup>/L or ANC less than 500/uL: No day 8 dose given.
**Subsequent cycles would be given at full dose if patients had platelets greater than or equal to 50 x 10<sup>9</sup>/L or ANC greater than or equal to 1000/uL.
**If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.
*[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV over 6 to 10 minutes once per day on days 1 & 8 '''first medication given'''
*[[Pegylated liposomal doxorubicin (Doxil)]] 15 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 8 '''third medication given'''
====Supportive medications====
*''See dose modifications, below''
'''21-day cycle for 2 to 6 cycles'''
====Subsequent treatment====
*SD or better: HSCT (details not specified)
====Dose modifications====
*'''If febrile neutropenia occurs''': Decrease treatment by one dose level.
*'''If febrile neutropenia occurs on dose level -1''': treating physician can choose to either:
*#Use filgrastim or sargramostim
*#Reduce dose of gemcitabine and vinorelbine by 25% for all subsequent cycles.
*'''If febrile neutropenia reoccurred despite dose reduction''' patient were discontinued from this protocol.

===Variant #2, post-transplant {{#subobject:1c824d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/6/1071.long Bartlett et al. 2007 (CALGB 59804)]
| style="background-color:#91cf61" |Phase I/II
|-
|}
''Note: this corresponds to dose level -1 used in the dose-finding portion of the protocol; see paper for further details.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8 '''second medication given'''
**If on day 8, platelets are 50 to 100 x 10<sup>9</sup>/L or ANC 500 to 1000/uL: reduce dose by 25% for that dose only.
**If on day 8, platelets are less than 50 x 10<sup>9</sup>/L or ANC less than 500/uL: No day 8 dose given.
**Subsequent cycles would be given at full dose if patients had platelets greater than or equal to 50 x 10<sup>9</sup>/L or ANC greater than or equal to 1000/uL.
**If counts were not adequate, the next cycle can be delayed for up to 3 weeks until counts are adequate for treatment.
*[[Vinorelbine (Navelbine)]] 15 mg/m<sup>2</sup> IV over 6 to 10 minutes once per day on days 1 & 8 '''first medication given'''
*[[Pegylated liposomal doxorubicin (Doxil)]] 10 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 8 '''third medication given'''
====Supportive medications====
*''See dose modifications, below''

'''21-day cycle for 2 to 6 cycles'''

====Dose modifications====
*'''If febrile neutropenia occurs''': Decrease treatment by one dose level.
*'''If febrile neutropenia occurs on dose level -1''': treating physician can choose to either:
*#Use filgrastim or sargramostim
*#Reduce dose of gemcitabine and vinorelbine by 25% for all subsequent cycles.
*'''If febrile neutropenia reoccurred despite dose reduction''' patient were discontinued from this protocol.

===References===
# '''CALGB 59804:''' Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun;18(6):1071-9. [http://annonc.oxfordjournals.org/content/18/6/1071.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17426059 PubMed]

==GVP {{#subobject:64fd2f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GVP: '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine, '''<u>P</u>'''rednisolone

===Regimen {{#subobject:a711d6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/23763798 Naqi et al. 2013]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV over 6 to 10 minutes once per day on days 1 & 8
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

'''28-day cycle for 4 cycles'''

===References===
# Naqi N, Ahmad S, Shah I, Khattak J. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma. J Coll Physicians Surg Pak. 2013 Jun;23(6):397-400. [https://www.ncbi.nlm.nih.gov/pubmed/23763798 PubMed]

==ICE {{#subobject:3bc734|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ICE: '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide

===Variant #1 {{#subobject:e896b3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://bloodjournal.hematologylibrary.org/content/97/3/616.long Moskowitz et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''admixed with [[Mesna (Mesnex)]]'''
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV once on day 2
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''admixed with [[Ifosfamide (Ifex)]]'''
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 5 to 12
*No dose reductions--treatment is delayed until ANC is greater than 1000/uL and platelets greater than 50 x 10<sup>9</sup>/L

'''14-day cycle for 2 cycles'''

===Variant #2, "Augmented ICE" {{#subobject:659c79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70013-6/fulltext Moskowitz et al. 2015 (MSK 11-142)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#Brentuximab_vedotin_monotherapy_2|Brentuximab vedotin]]
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 1, '''admixed with [[Mesna (Mesnex)]]''' (total dose per cycle: 10,000 mg/m<sup>2</sup>)
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 3
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV every 12 hours on day 1 (3 doses total)

====Supportive medications====
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup>/day IV continuous infusion over 48 hours, started on day 1, '''admixed with  [[Ifosfamide (Ifex)]]''' (total dose per cycle: 10,000 mg/m<sup>2</sup>)

'''2 cycles'''
====Subsequent treatment====
*Autologous hematopoietic cell transplant was "considered" after 2 cycles; criteria not listed in the abstract

===References===
# Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001 Feb 1;97(3):616-23. [http://bloodjournal.hematologylibrary.org/content/97/3/616.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11157476 PubMed]
<!-- # '''Abstract:''' Heiko Schoder, John F. Gerecitano, Paul Hamlin, Steven M. Horwitz, Matthew J Matasar, Vahakn S Keskinyan, Susan McCall, Ariela Noy, M. Lia Palomba, Carol S. Portlock, David J Straus, Joachim Yahalom, Anas Younes, Andrew D Zelenetz, Craig H. Moskowitz. FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma. Blood Nov 2013,122(21)2099 [http://bloodjournal.hematologylibrary.org/content/122/21/2099 link to abstract] -->
# '''MSK 11-142:''' Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. Epub 2015 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70013-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25683846 PubMed]

==Ifosfamide & Vinorelbine {{#subobject:76c9fb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:c54aaa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1998.00989.x/full Bonfante et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''admixed with [[Mesna (Mesnex)]]''' (total dose per cycle: 12,000 mg/m<sup>2</sup>)
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 5

====Supportive medications====
*[[Mesna (Mesnex)]] 3000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''admixed with [[Ifosfamide (Ifex)]]''' (total dose per cycle: 12,000 mg/m<sup>2</sup>)
*[[Prednisone (Sterapred)]] 50 mg IV once per day on days 1 to 5
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 7 to 14

'''21-day cycles'''

===References===
# Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5. [https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1998.00989.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9827930 PubMed]

==IGEV {{#subobject:5bdd8a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IGEV: '''<u>I</u>'''fosfamide, '''<u>GE</u>'''mcitabine, '''<u>V</u>'''inorelbine
===Regimen {{#subobject:d47b66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/92/1/35.long Santoro et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|[http://jco.ascopubs.org/content/34/12/1376.full Zinzani et al. 2016 (HD0801)]
| style="background-color:#91cf61" |Non-randomized
|-
|}
====Preceding treatment====
*HD0801: [[#ABVD_4|ABVD]] x 2
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 4

====Supportive medications====
*2L saline solution hyperhydration days 1 to 4
*[[Mesna (Mesnex)]] 2600 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Filgrastim (Neupogen)]] (dose not specified, but could assume 5 mcg/kg) SC once per day on days 7 to 12, or up to apheresis in the course of hematopoietic cell mobilization

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*HD0801, patients with CR: [[#BEAM.2C_then_auto_HSCT|BEAM, then autologous HSCT]]

===References===
# Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007 Jan;92(1):35-41. [http://www.haematologica.org/content/92/1/35.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17229633 PubMed]
# '''HD0801:''' Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016 Apr 20;34(12):1376-85. Epub 2016 Feb 16. [http://jco.ascopubs.org/content/34/12/1376.full link to original article] '''refers to Santoro et al. 2007''' [https://www.ncbi.nlm.nih.gov/pubmed/26884559 PubMed]

==Lenalidomide monotherapy {{#subobject:e47123|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:fd382f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217400/ Fehniger et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] (81 or 325 mg) PO once per day as prophylactic anticoagulation; those "deemed to be at high risk of deep venous thrombosis by the treating physician" were given [[Warfarin (Coumadin)]] or [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]]. 

'''28-day cycles'''

===References===
# Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10;118(19):5119-25. Epub 2011 Sep 21. [http://www.bloodjournal.org/content/118/19/5119.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217400/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21937701 PubMed]

==MINE {{#subobject:8ff2a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MINE: '''<u>M</u>'''esna, '''<u>I</u>'''fosfamide, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>E</u>'''toposide
===Regimen {{#subobject:bcf027|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/6/6/609.long Rodriguez et al. 1995]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 1333 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3, '''admixed with [[Mesna (Mesnex)]]'''
*[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 65 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3
====Supportive medications====
*[[Mesna (Mesnex)]] as follows:
**1333 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 3, '''admixed with [[Ifosfamide (Ifex)]]''' 
**500 mg PO 4 hours after each IV dose of [[Ifosfamide (Ifex)]] once per day on days 1 to 3 
'''3 to 4-week cycle for up to 6 cycles in responding patients'''

===References===
# Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul;6(6):609-11. [http://annonc.oxfordjournals.org/content/6/6/609.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8573542 PubMed]

==Mini-BEAM {{#subobject:e05c77|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Mini-BEAM: dose-reduced '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan

===Variant #1, 1 day of treatment/cycle {{#subobject:19e6c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/84/11/1007.long Fernández-Jiménez et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 300 mg/m<sup>2</sup> IV once on day 1
*[[Cytarabine (Cytosar)]] 800 mg/m<sup>2</sup> IV once on day 1
*[[Melphalan (Alkeran)]] 30 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 2 to 3 cycles'''

===Variant #2, 6 days of treatment/cycle {{#subobject:ef06d4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/13/2/396.long Colwill et al. 1995]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV over 30 minutes once on day 1
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV over 30 minutes once per day on days 2 to 5
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV every 12 hours on days 2 to 5
*[[Melphalan (Alkeran)]] 30 mg/m<sup>2</sup> IV over 15 minutes once on day 6

====Supportive medications====
*'''If febrile neutropenia occurred during previous cycle''': [[Ciprofloxacin (Cipro)]] 500 mg PO once per day
*Patients were transfused to keep Hb greater than or equal to 8 g/dL, platelets greater than or equal to 20 x 10<sup>9</sup>/L
*There was no routine use of G-CSF or GM-CSF

'''4 to 6 week cycles, depending on hematologic recovery'''

''Patients eligible for autologous hematopoietic cell transplant received no more than 2 cycles; otherwise total # of cycles not reported''

===References===
# Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24;341(8852):1051-4. [https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)92411-L/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8096958 PubMed] 
# Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM, Scott JG, Sutcliffe SB, Brandwein JM, Keating A. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995 Feb;13(2):396-402. [http://jco.ascopubs.org/content/13/2/396.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7844600 PubMed]
# Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica. 1999 Nov;84(11):1007-11. [http://www.haematologica.org/content/84/11/1007.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10553161 PubMed]
## '''Update:''' Martín A, Fernández-Jiménez MC, Caballero MD, Canales MA, Pérez-Simón JA, García de Bustos J, Vázquez L, Hernández-Navarro F, San Miguel JF. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001 Apr;113(1):161-71. [https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02714.x/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11328296 PubMed]

==Nivolumab monotherapy {{#subobject:73157d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, every 2 weeks {{#subobject:652fd5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30167-X/fulltext Younes et al. 2016 (CheckMate 205)]
| style="background-color:#91cf61" |Phase II
|style="background-color:#bfd3e6"|ORR: 66% (95% CI, 55-76)
|-
|}
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV every 2 weeks

'''Continued indefinitely'''

===Variant #2, with lead-in {{#subobject:1a2dff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009/ Ansell et al. 2014 (CheckMate 039)]
| style="background-color:#91cf61" |Phase I, >20 pts
|style="background-color:#e0ecf4"|ORR: 87%
|-
|}
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once per week on week 1, week 4, and then every 2 weeks

'''Continued for up to 2 years or complete response'''

===References===
# '''Phase 1:''' Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9. Epub 2014 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1411087 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25482239 PubMed]
# '''CheckMate 205:''' Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283-94. Epub 2016 Jul 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30167-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27451390 PubMed]

==O-ESHAP {{#subobject:f4f1c4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-ESHAP: '''<u>O</u>'''fatumumab, '''<u>E</u>'''toposide, '''<u>S</u>'''olumedrol (Methylprednisolone) '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)

===Regimen {{#subobject:30bbcc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14133/abstract Martínez et al. 2016]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note that the ofatumumab dosing is described in the abstract but the ESHAP is not. The ESHAP doses here are from the protocol defined by [http://jco.ascopubs.org/content/12/6/1169.long Velasquez et al. 1994].''
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 1000 mg IV once per day on days 1 & 8
**Cycles 2 & 3: 1000 mg IV once on day 1
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
*[[Methylprednisolone (Solumedrol)]] 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 5
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>) 

'''Number of cycles not specified'''

===References===
# Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6):859-67. 2016 May 17. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14133/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27185197 PubMed]

==Panobinostat monotherapy {{#subobject:ba10d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:0c34a8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/18/2197.long Younes et al. 2012]
| style="background-color:#91cf61" |Phase II
|Investigator assessment: 27% <br>Central review: 22%
|-
|}
''Patients had progressed after auto HSCT and had a median of 4 prior systemic regimens (range 2 to 7).''
====Chemotherapy====
*[[Panobinostat (Farydak)]] 40 mg PO three times per week (e.g., MWF)

'''21-day cycles'''

===References===
# Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2197-203. Epub 2012 Apr 30. [http://jco.ascopubs.org/content/30/18/2197.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547596 PubMed]

==Pembrolizumab monotherapy {{#subobject:85b287|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b29460|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1316 Chen et al. 2017 (KEYNOTE-087)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#bfd3e6" |ORR: 69%
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1

'''21-day cycles for up to 2 years'''

===References===
<!-- # '''Abstract:''' Moskowitz, C. H., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Radford, J. A., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Gustafson, E., Zhang, Y., Ricart, A. D., Balakumaran, A., & Chen, R. W. (2016). Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood, 128(22), 1107. [http://www.bloodjournal.org/content/128/22/1107 link to abstract] -->
# '''KEYNOTE-087:''' Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. Epub 2017 Apr 25. [http://ascopubs.org/doi/full/10.1200/JCO.2016.72.1316 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28441111 PubMed]

==Rituximab monotherapy {{#subobject:4ca4db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a6f461|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11511/full Younes et al. 2003]
| style="background-color:#91cf61" |Pilot, >20 pts
|-
|}

''Patients had received a minimum of 2 prior systemic regimens. All reported patients had nodular sclerosis histology.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week

'''6-week course (6 doses total)'''

===References===
# Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15;98(2):310-4. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11511/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12872350 PubMed]

==Vinblastine monotherapy {{#subobject:fbf642|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:32bbfa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/16/2/584.long Little et al. 1998]
| style="background-color:#ffffbe" |Retrospective
|-
|}
''This is a retrospective study; we are not aware of a prospective trial of vinblastine monotherapy in this setting.''
====Chemotherapy====
*[[Vinblastine (Velban)]] 4 to 6 mg/m<sup>2</sup> IV once on day 1

'''1 to 2-week cycles'''

===References===
# '''Retrospective:''' Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998 Feb;16(2):584-8. [http://jco.ascopubs.org/content/16/2/584.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9469345 PubMed]

==Vinorelbine monotherapy {{#subobject:e7b4a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:cb6ce1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/5/9/817.long Devizzi et al. 1994]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: Complete responders received 6 additional doses past CR; others continued until progression or a maximum of 24 doses.''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV bolus once per week

'''Up to 24-week course (see note)'''

===References===
# Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994 Nov;5(9):817-20. [http://annonc.oxfordjournals.org/content/5/9/817.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7531487 PubMed]

=Consolidation after salvage therapy=

==BEAM, then allo HSCT {{#subobject:bda306|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan

===Regimen {{#subobject:a8d4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2013.838233 Sobol et al. 2013]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|a8d4a}}
===References===
# Sobol U, Rodriguez T, Smith S, Go A, Vimr R, Parthasarathy M, Guo R, Stiff P. Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma. 2014 Jun;55(6):1281-7. Epub 2013 Oct 3. [https://www.tandfonline.com/doi/full/10.3109/10428194.2013.838233 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23987822 PubMed]

==BEAM, then auto HSCT {{#subobject:ed61ad|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:9fff3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)92411-L/fulltext Linch et al. 1993]
| style="background-color:#1a9851" |Phase III (E)
|[[#Mini-BEAM|Mini-BEAM]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08938-9/fulltext Schmitz et al. 2002 (GHSG HD-R1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#DexaBEAM|DexaBEAM]]
| style="background-color:#91cf60" |Seems to have superior FFTF
|-
|}
''Linch et al. 1993 was closed early due to patient request for the HSCT arm; dosing details are not available in the abstract.''
====Preceding treatment====
*GHSG HD-R1: [[#DexaBEAM|DexaBEAM]] x 2
{{#lst:Autologous HSCT|5e3c75}}
===References===
# Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24;341(8852):1051-4. [https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)92411-L/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8096958 PubMed] 
# '''GHSG HD-R1:''' Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08938-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12086759 PubMed]

==BeEAM, then auto HSCT {{#subobject:dee72f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BeEAM: '''<u>Be</u>'''ndamustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:81ff2e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/118/12/3419.long Visani et al. 2011]
| style="background-color:#ffffbe" |Phase I/II, <20 pts in this subgroup
|-
|}
{{#lst:Autologous HSCT|81ff2e}}
===References===
# Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419-25. Epub 2011 Aug 3. [http://www.bloodjournal.org/content/118/12/3419.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21816830 PubMed]

==CBV, then auto HSCT {{#subobject:935235|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CBV: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide)
===Variant #1, 1500/300/250, all BSA-based {{#subobject:1ba6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/88/5/522.long Zinzani et al. 2003]
| style="background-color:#ffffbe" |Retrospective
|-
|}
{{#lst:Autologous HSCT|1ba6d}}
===Variant #2, 1800/600/400 {{#subobject:cf6828|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/83/5/1193.long Reece et al. 1994]
| style="background-color:#ffffbe" |Phase II, <20 pts
|-
|}
{{#lst:Autologous HSCT|cf6828}}
===References===
# Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Phillips GL. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood. 1994 Mar 1;83(5):1193-9. [http://www.bloodjournal.org/content/83/5/1193.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8118023 PubMed]
# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica. 2003 May;88(5):522-8. [http://www.haematologica.org/content/88/5/522.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12745271 PubMed]

==CBV-Mx, then auto HSCT {{#subobject:77feb1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CBV-Mx: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide), '''<u>M</u>'''ito'''<u>x</u>'''antrone
===Regimen {{#subobject:8271c4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/26/36/5980.long Morschhauser et al. 2008 (GELA/SFGM H96)]
| style="background-color:#91cf61" |Non-randomized
|-
|}
{{#lst:Autologous HSCT|8271c4}}
===References===
# '''GELA/SFGM H96:''' Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008 Dec 20;26(36):5980-7. Epub 2008 Nov 17. [http://jco.ascopubs.org/content/26/36/5980.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19018090 PubMed]
## '''Update:''' Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016 Apr;101(4):474-81. Epub 2015 Dec 31. [http://www.haematologica.org/content/101/4/474 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004408/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26721893 PubMed]

==FEAM, then auto HSCT {{#subobject:0aac6f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEAM: '''<u>F</u>'''otemustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:74d43c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html Musso et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053328/ Musso et al. 2015]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Autologous HSCT|74d43c}}
===References===
# Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. Epub 2009 Nov 9. [https://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19898504 PubMed]
# Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016 Jan;172(1):111-21. Epub 2015 Oct 12. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13803/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053328/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26458240 PubMed]

==Flu-Mel, then allo HSCT {{#subobject:6f8499|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Flu-Mel: '''<u>Flu</u>'''darabine & '''<u>Mel</u>'''phalan
===Variant #1, 132/140 {{#subobject:72859b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238917/ Anderlini et al. 2008]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: the regimen as reported here is what the authors were using towards the end of the study period; see paper for details.''
====Preceding treatment====
*Salvage treatment (not specified), with chemosensitive or stable disease
{{#lst:Allogeneic HSCT|efd75c}}
===Variant #2, 150/140 {{#subobject:4f9a6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bbmt.org/article/S1083-8791(05)00673-7/fulltext Alvarez et al. 2006]
| style="background-color:#91cf61" |Prospective
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269494/ Sureda et al. 2011 (HDR-ALLO)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*Alvarez et al. 2006: Not specified
*HDR-ALLO: [[#DHAP|DHAP]] x 2
{{#lst:Allogeneic HSCT|3239ec}}
===References===
# Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. [http://www.bbmt.org/article/S1083-8791(05)00673-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16443515 PubMed]
# Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica. 2008 Feb;93(2):257-64. Epub 2008 Jan 26. [http://www.haematologica.org/content/93/2/257.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238917/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18223284 PubMed] 
# '''HDR-ALLO:''' Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma: results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012 Feb;97(2):310-7. Epub 2011 Oct 11. [http://www.haematologica.org/content/97/2/310.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269494/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21993674 PubMed]

==Fludarabine, Melphalan, Alemtuzumab, then allo HSCT {{#subobject:99386e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:149798|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140673605666597/fulltext Peggs et al. 2005]
| style="background-color:#91cf61" |Non-randomized
|-
|}
{{#lst:Allogeneic HSCT|149798}}
===References===
# Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson KJ, Morris EC, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005 Jun 4-10;365(9475):1934-41. [https://www.thelancet.com/journals/lancet/article/PIIS0140673605666597/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15936420 PubMed]

==Radiation therapy {{#subobject:e31a6e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, involved node RT (INRT) {{#subobject:879d61|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/32/12/1188.long Raemaekers et al. 2014 (EORTC/LYSA/FIL H10)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#eBEACOPP_3|eBEACOPP]] x 2
====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy (+ 6 Gy boost)

===Variant #2, involved field RT (IFRT) {{#subobject:2f3de6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 Radford et al. 2015 (UK NCRI RAPID)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#ABVD|ABVD]] x 4
====Radiotherapy====
*[[External beam radiotherapy]] 30 Gy

===References===
<!-- Presented (preliminary results) at the 51st Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA, December 5-8, 2009; Eighth International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 23-26, 2010; and 54th ASH Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94. Epub 2014 Mar 17. [http://jco.ascopubs.org/content/32/12/1188.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24637998 PubMed]
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] -->
# '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://www.nejm.org/doi/full/10.1056/NEJMoa1408648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25901426 PubMed]

=Maintenance after salvage therapy=
==Brentuximab vedotin monotherapy {{#subobject:33b236|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60165-9/fulltext Moskowitz et al. 2015 (AETHERA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Treatment begins 30 to 45 days after transplant.''
====Preceding treatment====
*Autologous HSCT (preparative regimen not specified)
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV once on day 1

'''21-day cycle for 16 cycles'''

===References===
# '''AETHERA:''' Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60165-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25796459 PubMed]
## '''HRQoL analysis:''' Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. Epub 2016 Sep 21. [https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14316 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621593/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27649689 PubMed]
## '''Update:''' Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. Epub 2018 Sep 28. [http://www.bloodjournal.org/content/132/25/2639.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30266774 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60165-9/fulltext Moskowitz et al. 2015 (AETHERA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Brentuximab_vedotin_monotherapy_3|Brentuximab vedotin]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428194.2016.1182164 von Treskckow et al. 2016 (PATH)]
| style="background-color:#1a9851" |Phase III (C)
|Panobinostat
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''No further active antineoplastic treatment after transplant. Note that PATH had a very low accrual and was not powered to investigate the original primary endpoint (DFS).''
====Preceding treatment====
*Autologous HSCT (preparative regimen not specified)

===References===
# '''AETHERA:''' Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60165-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25796459 PubMed]
## '''HRQoL analysis:''' Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. Epub 2016 Sep 21. [https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14316 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621593/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27649689 PubMed]
## '''Update:''' Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. Epub 2018 Sep 28. [http://www.bloodjournal.org/content/132/25/2639.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30266774 PubMed]
# '''PATH:''' von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. [https://www.tandfonline.com/doi/full/10.1080/10428194.2016.1182164 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27184350 PubMed]

=Response criteria=

==NCI Sponsored International Working Group Criteria (1999)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Intended for non-Hodgkin lymphoma (NHL) but often referred to in the Hodgkin lymphoma literature.''
# Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/17/4/1244.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561185 PubMed]

==International Harmonization Project on Lymphoma (2007)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.2403 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17242396 PubMed]

==Juweid's criteria (2007)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
# Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10;25(5):571-8. Epub 2007 Jan 22. [http://jco.ascopubs.org/content/25/5/571.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17242397 PubMed]

==Deauville criteria (2009)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Note: the definition of "positive" versus "negative" varies and should be confirmed within individual protocols. This is a 5-point scale.''
*'''1:''' no residual FDG uptake above the background level
*'''2:''' residual FDG uptake less than or equal to the mediastinum
*'''3:''' residual FDG uptake greater than the mediastinum but not greater than the liver
*'''4:''' residual FDG uptake moderately increased compared with the liver
*'''5:''' residual FDG uptake markedly increased compared with the liver or new sites of disease. 
===References===
# Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009 Aug;50(8):1257-60. [http://www.tandfonline.com/doi/full/10.1080/10428190903040048 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19544140 PubMed]
# Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, Almquist H, Loft A, Højgaard L, Federico M, Gallamini A, Smith P, Johnson P, Radford J, O'Doherty MJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33. Epub 2010 May 27. [http://link.springer.com/article/10.1007%2Fs00259-010-1490-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20505930 PubMed]
# Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013 May;54(5):683-90. Epub 2013 Mar 20. [http://jnm.snmjournals.org/content/54/5/683.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23516309 PubMed]

=Investigational agents=
*[[Fotemustine (Muphoran)]]
*[[Mocetinostat (MGCD0103)]]

[[Category:Hodgkin lymphoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Aggressive lymphomas]]
